<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006780.pub2" GROUP_ID="PREG" ID="296906111011013426" MERGED_FROM="" MODIFIED="2013-07-17 15:26:51 +0100" MODIFIED_BY="Leanne Jones" REVIEW_NO="0554" REVMAN_SUB_VERSION="5.2.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2013-07-17 15:26:51 +0100" MODIFIED_BY="Leanne Jones">
<TITLE>Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction</TITLE>
<CONTACT MODIFIED="2013-07-17 15:26:51 +0100" MODIFIED_BY="Leanne Jones"><PERSON ID="15882" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Jodie</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Dodd</LAST_NAME><POSITION>Maternal Fetal Medicine Subspecialist and NH&amp;MRC Neil Hamilton Fairley Fellow</POSITION><EMAIL_1>jodie.dodd@adelaide.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>School of Paediatrics and Reproductive Health, Discipline of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>The University of Adelaide</ORGANISATION><ADDRESS_1>Women's and Children's Hospital</ADDRESS_1><ADDRESS_2>72 King William Road</ADDRESS_2><CITY>Adelaide</CITY><ZIP>5006</ZIP><REGION>South Australia</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 8 81617647</PHONE_1><FAX_1>+61 8 81617652</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-07-17 15:26:51 +0100" MODIFIED_BY="Leanne Jones"><PERSON ID="15882" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Jodie</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Dodd</LAST_NAME><POSITION>Maternal Fetal Medicine Subspecialist and NH&amp;MRC Neil Hamilton Fairley Fellow</POSITION><EMAIL_1>jodie.dodd@adelaide.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>School of Paediatrics and Reproductive Health, Discipline of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>The University of Adelaide</ORGANISATION><ADDRESS_1>Women's and Children's Hospital</ADDRESS_1><ADDRESS_2>72 King William Road</ADDRESS_2><CITY>Adelaide</CITY><ZIP>5006</ZIP><REGION>South Australia</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 8 81617647</PHONE_1><FAX_1>+61 8 81617652</FAX_1></ADDRESS></PERSON><PERSON ID="7E97EDC082E26AA2007D5B6E5F54BE4D" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Anne</FIRST_NAME><LAST_NAME>McLeod</LAST_NAME><POSITION>Haematologist</POSITION><EMAIL_1>anne.mcleod@sunnybrook.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medicine</DEPARTMENT><ORGANISATION>University of Toronto</ORGANISATION><CITY>Toronto</CITY><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON><PERSON ID="EDFD973882E26AA201CF22BB7822CEE2" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Rory</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Windrim</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>rwindrim@mtsinai.on.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>University of Toronto</ORGANISATION><CITY>Toronto</CITY><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON><PERSON ID="7E994B7B82E26AA2007D5B6E86EC1C4F" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>John</FIRST_NAME><LAST_NAME>Kingdom</LAST_NAME><POSITION>Professor of Obstetrics and Gynecology</POSITION><EMAIL_1>jkingdom@mtsinai.on.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>University of Toronto</ORGANISATION><CITY>Toronto</CITY><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-06-12 15:40:03 +0100" MODIFIED_BY="Lynn Hampson">
<UP_TO_DATE>
<DATE DAY="24" MONTH="10" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="17" MONTH="7" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="1" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="6" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="6" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2013-07-16 15:56:34 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-05-21 16:13:50 +0100" MODIFIED_BY="Denise Atherton">
<DATE DAY="28" MONTH="8" YEAR="2012"/>
<DESCRIPTION>
<P>Search updated July 2012.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2013-07-16 15:56:34 +0100" MODIFIED_BY="Denise Atherton">
<DATE DAY="28" MONTH="8" YEAR="2012"/>
<DESCRIPTION>
<P>The updated review includes an additional five randomised trials which has changed the conclusions of the review.</P>
<P>In this 2013 update, there is no evidence of a difference in pre-eclampsia and evidence for a reduction in perinatal mortality and preterm birth before 34 and 37 weeks.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-06-25 14:24:09 +0100" MODIFIED_BY="Denise Atherton">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-06-25 14:24:09 +0100" MODIFIED_BY="Denise Atherton">
<DATE DAY="17" MONTH="7" YEAR="2012"/>
<DESCRIPTION>
<P>Search updated. Eight reports of seven trials added to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK> (Gris 2010a; Gris 2011a; Kingdom 2011a; Martinelli 2012a; Walker 2011a; <LINK REF="STD-Yu-2004b" TYPE="STUDY">Yu 2004b</LINK>; Yu 2010a).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2009-10-09 11:40:56 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2009-10-09 11:40:56 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2009-10-09 11:40:56 +0100" MODIFIED_BY="[Empty name]">
<NAME>Discipline of Obstetrics and Gynaecology, The University of Adelaide</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2009-09-17 07:14:43 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2009-09-17 07:14:43 +0100" MODIFIED_BY="[Empty name]">
<NAME>Neil Hamilton Fairley Fellowship supported by the NHMRC (ID 399224)</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-07-17 14:51:29 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-07-12 17:16:49 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-09-25 15:38:22 +0100" MODIFIED_BY="Sonja L  Henderson">Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction</TITLE>
<SUMMARY_BODY MODIFIED="2013-07-12 17:16:49 +0100" MODIFIED_BY="[Empty name]">
<P>Pregnancy complications such as pre-eclampsia and eclampsia, intrauterine fetal growth restriction and placental abruption are thought to be related to abnormalities in the development and function of the placenta. Treatment with heparin to prevent the development of blood clots within the placenta appears to be a promising intervention to prevent these complications. The numbers of pregnant women with pre-eclampsia, preterm birth, perinatal death and a low birthweight infant (weighing less than the 10th centile for gestational age) were reduced with this treatment. Ten randomised trials involving 1139 women met the inclusion criteria for the review. Nine studies compared heparin (alone or in combination with dipyridamole) with no treatment; and one compared triazolopyrimidine with placebo. The most commonly recognised side effect for women related to this treatment was mild skin bruising. To date, important information about serious adverse infant and long-term childhood outcomes with using anti-clotting medications is unavailable. Further research is required.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-07-12 17:15:58 +0100" MODIFIED_BY="Lynn Hampson">
<ABS_BACKGROUND MODIFIED="2009-09-17 08:25:53 +0100" MODIFIED_BY="[Empty name]">
<P>Pregnancy complications such as pre-eclampsia and eclampsia, intrauterine growth restriction and placental abruption are thought to have a common origin related to abnormalities in the development and function of the placenta.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-09-17 08:26:13 +0100" MODIFIED_BY="[Empty name]">
<P>To compare, using the best available evidence, the benefits and harms of antenatal antithrombotic therapy to improve maternal or infant health outcomes in women considered at risk of placental dysfunction, when compared with other treatments, placebo or no treatment.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-06-18 12:31:35 +0100" MODIFIED_BY="Lynn Hampson">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (17 July 2012).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-09-17 08:27:08 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials comparing antenatal antithrombotic therapy (either alone or in combination with other agents) with placebo or no treatment, or any other treatment in the antenatal period to improve maternal or infant health outcomes in women considered at risk of placental dysfunction.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-07-12 17:13:40 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors evaluated trials under consideration for appropriateness for inclusion and methodological quality without consideration of their results according to the prestated eligibility criteria. We used a fixed-effect meta-analysis for combining study data if the trials were judged to be sufficiently similar. We investigated heterogeneity by calculating I² statistic, and if this indicated a high level of heterogeneity among the trials included, we used a random-effects model.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-06-24 16:24:14 +0100" MODIFIED_BY="[Empty name]">
<P>Our search strategy identified 18 reports of 14 studies for consideration. The original review included five studies (484 women) which met the inclusion criteria, with a further five studies included in the updated review, involving an additional 655 women. The overall quality of the included trials was considered fair to good.</P>
<P>Nine studies compared heparin (alone or in combination with dipyridamole or low-dose aspirin) with no treatment; and one compared trapidil (triazolopyrimidine).</P>
<P>While this review identified the use of heparin to be associated with a statistically significant reduction in risk of perinatal mortality (six studies; 653 women; risk ratio (RR) 0.40; 95% confidence intervals (CI) 0.20 to 0.78), preterm birth before 34 (three studies; 494 women; RR 0.46; 95% CI 0.29 to 0.73) and 37 (five studies; 621 women; RR 0.72; 95% CI 0.58 to 0.90) weeks' gestation, and infant birthweight below the 10th centile for gestational age (seven studies; 710 infants; RR 0.41; 95% CI 0.27 to 0.61), there is a lack of reliable information available related to clinically relevant, serious adverse infant health outcomes, which have not been reported to date.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-07-12 17:15:58 +0100" MODIFIED_BY="[Empty name]">
<P>While treatment with heparin for women considered to be at particularly high risk of adverse pregnancy complications secondary to placental insufficiency was associated with a statistically significant reduction in risk of perinatal mortality, preterm birth before 34 and 37 weeks' gestation, and infant birthweight below the 10th centile for gestational age when compared with no treatment for women considered at increased risk of placental dysfunction, to date, important information about serious adverse infant and long-term childhood outcomes is unavailable.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-07-16 15:50:57 +0100" MODIFIED_BY="Lynn Hampson">
<BACKGROUND MODIFIED="2013-07-12 17:40:38 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2013-07-12 17:18:27 +0100" MODIFIED_BY="[Empty name]">
<P>Pregnancy complications such as pre-eclampsia and eclampsia, restricted growth of the baby in the uterus (intrauterine fetal growth restriction (IUGR)) and placental abruption are thought to be related to problems with the development and function of the placenta. Pre-eclampsia and its complications remain a common cause of maternal and infant morbidity and mortality throughout the world (<LINK REF="REF-Sibai-2005" TYPE="REFERENCE">Sibai 2005</LINK>). Infants born to women with pre-eclampsia have an increased risk of IUGR, preterm birth and perinatal mortality (<LINK REF="REF-Laws-2004" TYPE="REFERENCE">Laws 2004</LINK>). Infants who are small-for-gestational age (SGA) at birth are recognised to be at increased risk of adverse health outcomes (<LINK REF="REF-Bernstein-2000" TYPE="REFERENCE">Bernstein 2000</LINK>; <LINK REF="REF-McIntire-1999" TYPE="REFERENCE">McIntire 1999</LINK>), including mortality (<LINK REF="REF-Cnattingius-1998" TYPE="REFERENCE">Cnattingius 1998</LINK>; <LINK REF="REF-Kok-1998" TYPE="REFERENCE">Kok 1998</LINK>), birth hypoxia (<LINK REF="REF-Cnattingius-1998" TYPE="REFERENCE">Cnattingius 1998</LINK>), and developmental problems during infancy and childhood (<LINK REF="REF-Kok-1998" TYPE="REFERENCE">Kok 1998</LINK>; <LINK REF="REF-Roth-1999" TYPE="REFERENCE">Roth 1999</LINK>). The risk of infant mortality is further increased in both term and preterm infants in the presence of growth restriction (<LINK REF="REF-Tan-2005" TYPE="REFERENCE">Tan 2005</LINK>). Fetal growth restriction is estimated to complicate 5% to 10% of perinatal deaths, with over 75% of stillborn infants being of low birthweight (<LINK REF="REF-Laws-2004" TYPE="REFERENCE">Laws 2004</LINK>). For women and their families, the loss of a pregnancy through intrauterine fetal death is an emotionally devastating event.</P>
<P>Central to the development and continuation of a normal healthy pregnancy is the optimal development of the placenta. The placenta is required to form an effective exchange system for the transfer of oxygen, nutrients and waste products between the mother and the fetus (<LINK REF="REF-Khong-2004" TYPE="REFERENCE">Khong 2004</LINK>; <LINK REF="REF-Robson-2002" TYPE="REFERENCE">Robson 2002</LINK>). Crucial to this development is the transformation of the usually high resistance spiral arteries into large calibre, low resistance uteroplacental vessels by a process of extra-villous trophoblast infiltration (<LINK REF="REF-Burton-2009" TYPE="REFERENCE">Burton 2009</LINK>; <LINK REF="REF-Khong-2004" TYPE="REFERENCE">Khong 2004</LINK>; <LINK REF="REF-Robson-2002" TYPE="REFERENCE">Robson 2002</LINK>). When this process does not occur, the placenta that develops is small (<LINK REF="REF-Egbor-2006" TYPE="REFERENCE">Egbor 2006</LINK>; <LINK REF="REF-Khong-2004" TYPE="REFERENCE">Khong 2004</LINK>; <LINK REF="REF-Sander-2005" TYPE="REFERENCE">Sander 2005</LINK>; <LINK REF="REF-Toal-2008" TYPE="REFERENCE">Toal 2008</LINK>), and there is a poor maternal cardiovascular response to pregnancy, resulting in haemoconcentration, a lack of second trimester blood pressure reduction (<LINK REF="REF-Dekker-2005a" TYPE="REFERENCE">Dekker 2005a</LINK>; <LINK REF="REF-Sibai-2005" TYPE="REFERENCE">Sibai 2005</LINK>). These changes in the placenta precede the development of severe early-onset pre-eclampsia (<LINK REF="REF-Dekker-2001" TYPE="REFERENCE">Dekker 2001</LINK>; <LINK REF="REF-Dekker-2005a" TYPE="REFERENCE">Dekker 2005a</LINK>; <LINK REF="REF-Dekker-2005b" TYPE="REFERENCE">Dekker 2005b</LINK>; <LINK REF="REF-Sibai-2005" TYPE="REFERENCE">Sibai 2005</LINK>). Pathological examination of the placenta after birth, which has occurred secondary to pre-eclampsia or IUGR occurring in early pregnancy, may identify the presence of ischaemic thrombotic lesions, including infarction (or damage to the placental tissue due to clots forming in the placental blood vessels on the maternal side) (<LINK REF="REF-Ferrazzi-1999" TYPE="REFERENCE">Ferrazzi 1999</LINK>; <LINK REF="REF-Franco-2011" TYPE="REFERENCE">Franco 2011</LINK>; <LINK REF="REF-Viero-2004" TYPE="REFERENCE">Viero 2004</LINK>; <LINK REF="REF-Walker-2012" TYPE="REFERENCE">Walker 2012</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-07-12 17:18:35 +0100" MODIFIED_BY="[Empty name]">
<P>An intervention that may be able to prevent the development of vascular pathology (specifically to prevent the development of blood clots within the placenta and the subsequent death or infarction of placental tissue) may be effective in reducing the risk or preventing the development of clinical complications such as fetal death, pre-eclampsia or IUGR. Therapies that may be effective include the use of antithrombotic medications, which act by preventing the formation of blood clots, in addition to some immune mediating functions. These medications include unfractionated heparin (UFH), and low molecular weight heparin (LMWH), and are administered by injection below the skin of the abdomen (called subcutaneous injection).</P>
</INTERVENTION>
<THEORY MODIFIED="2013-07-12 17:40:38 +0100" MODIFIED_BY="[Empty name]">
<P>There have been a number of reports in the literature related to the use of antithrombotic medications in women with a history of placental infarction in a previous pregnancy, as a means of preventing placental dysfunction in a subsequent pregnancy, and improving infant outcomes (<LINK REF="REF-Alkazaleh-2004" TYPE="REFERENCE">Alkazaleh 2004</LINK>; <LINK REF="REF-Bonnar-1975" TYPE="REFERENCE">Bonnar 1975</LINK>; <LINK REF="REF-Buyse-1974" TYPE="REFERENCE">Buyse 1974</LINK>; <LINK REF="REF-Chupin-1978" TYPE="REFERENCE">Chupin 1978</LINK>; <LINK REF="REF-Fuke-1994" TYPE="REFERENCE">Fuke 1994</LINK> <LINK REF="REF-Moe-1982" TYPE="REFERENCE">Moe 1982</LINK>). These studies are in the form of case series and cohort studies, which have inherent bias, involve a small number of pregnant women only, and variably report important clinical outcomes. Furthermore, two reports (<LINK REF="REF-Bonnar-1975" TYPE="REFERENCE">Bonnar 1975</LINK>; <LINK REF="REF-Buyse-1974" TYPE="REFERENCE">Buyse 1974</LINK>) involved the use of warfarin from the second trimester of pregnancy before converting to heparin therapy from 36 weeks' gestation. Warfarin is an oral anticoagulant medication that is currently not recommended for use in pregnancy as it is associated with the development of fetal anomalies when used in the first trimester of pregnancy. The results of these case series and cohort studies should be interpreted with caution.</P>
<P>The use of antithrombotic medications, while potentially beneficial in reducing the occurrence of adverse pregnancy outcome, are not without potential harm. The most commonly recognised minor side effects for the woman related to antithrombotic therapy include local skin reactions and skin bruising (<LINK REF="REF-Greer-2006" TYPE="REFERENCE">Greer 2006</LINK>). More serious complications for the woman are uncommon with the relatively short-term use of medication as seen during pregnancy (<LINK REF="REF-Greer-2006" TYPE="REFERENCE">Greer 2006</LINK>). Other potential complications include bone loss (called osteopaenia), and subsequent osteoporotic bone fractures. These complications occur in less than 1% of patients exposed to long-term heparin therapy (rather than the short duration associated with use during pregnancy), and predominantly occur with the use of UFH (rather than LMWH) (<LINK REF="REF-Greer-2006" TYPE="REFERENCE">Greer 2006</LINK>). Heparin-induced thrombocytopenia (or a fall in platelet count; platelets are components of the blood which assist in clotting) is estimated to occur in less than 1% of women exposed to long-term heparin therapy, is reversible with cessation of medication, and again, is more common when UFH is used (<LINK REF="REF-Greer-2006" TYPE="REFERENCE">Greer 2006</LINK>). Placental bleeding or abruption has been reported to occur in 0.04% of women using long-term heparin therapy during pregnancy (<LINK REF="REF-Greer-2006" TYPE="REFERENCE">Greer 2006</LINK>). Furthermore, the use of heparin may be associated with an increased risk of bleeding at the time of epidural or spinal anaesthesia, as well as increasing risks of post-operative bleeding (<LINK REF="REF-Greer-2006" TYPE="REFERENCE">Greer 2006</LINK>). Antithrombotic medications, such as UFH and LMWH, do not cross the placenta, and are therefore, safe for the fetus when used during pregnancy (<LINK REF="REF-Greer-2006" TYPE="REFERENCE">Greer 2006</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-07-12 17:18:56 +0100" MODIFIED_BY="[Empty name]">
<P>While there may be benefits in the use of antenatal antithrombotic therapy for women considered to be at risk of complications related to placental dysfunction, in terms of improved maternal and infant health outcomes, there may also be harms related to the potential side effects of medication. The aim of this review is to use the best available evidence to assess the benefits and harms of antenatal antithrombotic therapy for women where the intention is to improve maternal or infant health outcomes associated with placental dysfunction when compared with other treatments, placebo or no treatment.</P>
<P>This review will not consider the use of heparin in pregnant women with acquired or inherited thrombophilias (predisposition to thrombosis) (<LINK REF="REF-Walker-2003" TYPE="REFERENCE">Walker 2003</LINK>), its use in recurrent miscarriage or recurrent pregnancy loss in women with (<LINK REF="REF-Empson-2005" TYPE="REFERENCE">Empson 2005</LINK>) or without (<LINK REF="REF-Kaandorp-2009" TYPE="REFERENCE">Kaandorp 2009</LINK>) antiphospholipid syndrome, or as prophylaxis for venous thromboembolic disease in pregnancy and the postpartum period (<LINK REF="REF-Gates-2002" TYPE="REFERENCE">Gates 2002</LINK>) as the use of antithrombotic agents for these indications are covered in other Cochrane reviews.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-04-20 13:48:56 +0100" MODIFIED_BY="[Empty name]">
<P>To compare, using the best available evidence, the benefits and harms of antenatal antithrombotic therapy to improve maternal or infant health outcomes in women considered at risk of placental dysfunction, when compared with other treatments, placebo, or no treatment.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-07-12 17:21:33 +0100" MODIFIED_BY="Lynn Hampson">
<SELECTION_CRITERIA MODIFIED="2013-07-12 17:19:07 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-07-12 17:19:07 +0100" MODIFIED_BY="[Empty name]">
<P>We considered for inclusion all published, unpublished, and ongoing randomised controlled trials (RCTs) comparing antenatal antithrombotic therapy (either alone or in combination with other agents) with placebo or no treatment, or any other treatment in the antenatal period to improve maternal or infant health outcomes in women considered at risk of placental dysfunction.</P>
<P>We excluded trials assessing the role of heparin in pregnant women with acquired or inherited thrombophilias, its use in recurrent miscarriage or recurrent pregnancy loss in women with or without antiphospholipid syndrome, or as prophylaxis for venous thromboembolic disease in pregnancy and the postpartum period. We excluded quasi-randomised trials (e.g. those randomised by date of birth or hospital number). We also excluded studies where low-dose aspirin was used alone. We included studies reported only in abstract form in the <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK> category; if relevant we will include these in the analyses when published as full reports.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-05-01 03:18:01 +0100" MODIFIED_BY="[Empty name]">
<P>Women undergoing antenatal treatment with antithrombotic therapy where the intention is to improve maternal or infant health outcomes in women considered at particularly high risk of complications related to placental dysfunction.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-09-17 01:08:37 +0100" MODIFIED_BY="[Empty name]">
<P>Antenatal antithrombotic therapy (alone or in combination with other agents) versus placebo or no treatment, or any other treatment in the antenatal period to improve maternal or infant health outcomes in women considered at risk of placental dysfunction. We considered for inclusion studies reporting comparisons between different antithrombotic agents or different doses of antithrombotic agents.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-06-18 12:37:56 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-06-18 12:37:56 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Perinatal mortality</LI>
<LI>Preterm birth (less than 34 weeks' gestation)</LI>
<LI>Major neurodevelopmental handicap at childhood follow-up</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-06-18 12:14:33 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Maternal</HEADING>
<UL>
<LI>Pre-eclampsia or eclampsia</LI>
<LI>Placental abruption</LI>
<LI>Antepartum haemorrhage (beyond 20 weeks and requiring hospital admission)</LI>
<LI>Length of antenatal stay</LI>
<LI>Use of antenatal corticosteroids for fetal lung maturation</LI>
<LI>Antibiotic use after birth</LI>
<LI>Postpartum haemorrhage (defined as blood loss greater than 500 mL at vaginal birth or greater than 1000 mL at caesarean birth)</LI>
<LI>Need for blood transfusion</LI>
<LI>Anaesthetic complications (as defined by trial authors)</LI>
<LI>Adverse drug reaction (including bruising, local skin reaction, minor haemorrhage, heparin-induced thrombocytopaenia, osteopaenia, bone fractures)</LI>
<LI>Maternal death</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Infant</HEADING>
<UL>
<LI>Birth before 37, 32, and 28 completed weeks</LI>
<LI>Birthweight less than the 10th centile for gestational age</LI>
<LI>Birthweight less than 2500 g</LI>
<LI>Apgar score of less than seven at five minutes</LI>
<LI>Respiratory distress syndrome</LI>
<LI>Use of mechanical ventilation</LI>
<LI>Duration of mechanical ventilation</LI>
<LI>Intraventricular haemorrhage - Grades III or IV</LI>
<LI>Periventricular leucomalacia</LI>
<LI>Retinopathy of prematurity</LI>
<LI>Retinopathy of prematurity - Grades III or IV</LI>
<LI>Chronic lung disease</LI>
<LI>Necrotising enterocolitis</LI>
<LI>Neonatal sepsis</LI>
<LI>Fetal death</LI>
<LI>Neonatal death</LI>
<LI>Admission to neonatal intensive care unit</LI>
<LI>Neonatal length of hospital stay</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-06-25 14:21:42 +0100" MODIFIED_BY="Lynn Hampson">
<ELECTRONIC_SEARCHES MODIFIED="2013-06-25 14:21:42 +0100" MODIFIED_BY="Lynn Hampson">
<P>We searched the Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register by contacting the Trials Search Co-ordinator (17 July 2012).</P>
<P>The Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from:</P>
<OL>
<LI>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>weekly searches of MEDLINE;</LI>
<LI>weekly searches of Embase;</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Details of the search strategies for CENTRAL, MEDLINE and Embase, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the &#8216;Specialized Register&#8217; section within the editorial information about the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html">Cochrane Pregnancy and Childbirth Group</A>.</P>
<P>Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords.</P>
<P>We did not apply any language restrictions.</P>
</ELECTRONIC_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-07-12 17:21:33 +0100" MODIFIED_BY="[Empty name]">
<P>For the methods used when assessing the trials identified in the previous version of this review, <I>see </I>
<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>For this update we used the following methods when assessing the reports identified by the updated search.</P>
<STUDY_SELECTION MODIFIED="2013-05-22 12:39:26 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed for inclusion all the potential studies we identified as a result of the search strategy. We resolved any disagreement through discussion or, if required, we consulted a third person.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-05-22 12:40:19 +0100" MODIFIED_BY="[Empty name]">
<P>We designed a form to extract data. For eligible studies, at least two review authors extracted the data using the agreed form. We resolved discrepancies through discussion or, if required, we consulted a third person. We entered data into Review Manager software (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>) and checked for accuracy.</P>
<P>When information regarding any of the above was unclear, we attempted to contact authors of the original reports to provide further details.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-07-12 17:19:46 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed risk of bias for each study using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions (</I>
<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We resolved any disagreement by discussion or by involving a third assessor.</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Random sequence generation (checking for possible selection bias)</HEADING>
<P>We described for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.</P>
<P>We assessed the method as:</P>
<UL>
<LI>low risk of bias (any truly random process, e.g. random number table; computer random number generator);</LI>
<LI>high risk of bias (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);</LI>
<LI>unclear risk of bias.   </LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(2) Allocation concealment (checking for possible selection bias)</HEADING>
<P>We described for each included study the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);</LI>
<LI>high risk of bias (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);</LI>
<LI>unclear risk of bias.   </LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3.1) Blinding of participants and personnel (checking for possible performance bias)</HEADING>
<P>We described for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding would be unlikely to affect results. We assessed blinding separately for different outcomes or classes of outcomes.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low, high or unclear risk of bias for participants;</LI>
<LI>low, high or unclear risk of bias for personnel.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3.2) Blinding of outcome assessment (checking for possible detection bias)</HEADING>
<P>We described for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes.</P>
<P>We assessed methods used to blind outcome assessment as:</P>
<UL>
<LI>low, high or unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data)</HEADING>
<P>We described for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We state whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information is reported, or can be supplied by the trial authors, we will re-include missing data in the analyses which we undertake.</P>
<P>We assessed methods as:</P>
<UL>
<LI>low risk of bias (e.g. no or low (less than 20%) missing outcome data; missing outcome data balanced across groups);</LI>
<LI>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; &#8216;as treated&#8217; analysis done with substantial departure of intervention received from that assigned at randomisation);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(5) Selective reporting (checking for reporting bias)</HEADING>
<P>We described for each included study how we investigated the possibility of selective outcome reporting bias and what we found.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk of bias (where it is clear that all of the study&#8217;s pre-specified outcomes and all expected outcomes of interest to the review have been reported);</LI>
<LI>high risk of bias (where not all the study&#8217;s pre-specified outcomes have been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)</HEADING>
<P>We described for each included study any important concerns we have about other possible sources of bias.</P>
<P>We assessed whether each study was free of other problems that could put it at risk of bias:</P>
<UL>
<LI>low risk of other bias;</LI>
<LI>high risk of other bias;</LI>
<LI>unclear whether there is risk of other bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(7) Overall risk of bias</HEADING>
<P>We made explicit judgements about whether studies are at high risk of bias, according to the criteria given in the <I>Cochrane</I> <I>Handbook</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered it likely to impact on the findings. We planned to explore the impact of the level of bias through undertaking sensitivity analyses - <I>see </I>
<LINK TAG="SENSITIVITY_ANALYSIS" TYPE="SECTION">Sensitivity analysis</LINK>. </P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-05-22 12:55:41 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>For dichotomous data, we presented results as summary risk ratio with 95% confidence intervals. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>For continuous data, we used the mean difference for outcomes measured in the same way between trials. In future updates, if appropriate, we will use the standardised mean difference to combine trials that measure the same outcome, but use different methods. <B> </B>
</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-07-12 17:19:56 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Cluster-randomised trials</HEADING>
<P>No cluster-randomised trials were included in this 2013 updated. In future updates, we will include cluster-randomised trials in the analyses along with individually-randomised trials. We will adjust their sample sizes using the methods described in the <I>Cochrane Handbook</I> Section 16.3.4 using an estimate of the intracluster correlation co-efficient (ICC) derived from the trial (if possible), from a similar trial or from a study of a similar population. If we use ICCs from other sources, we will report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identify both cluster-randomised trials and individually-randomised trials, we plan to synthesise the relevant information. We will consider it reasonable to combine the results from both if there is little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomisation unit is considered to be unlikely.</P>
<P>We will also acknowledge heterogeneity in the randomisation unit and perform a sensitivity analysis to investigate the effects of the randomisation unit.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cross-over trials</HEADING>
<P>Cross-over trials are not an appropriate study design in this setting and will not be included.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-05-22 13:03:31 +0100" MODIFIED_BY="[Empty name]">
<P>For included studies, we noted levels of attrition. We planned to explore the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis. This has not been performed for this update.</P>
<P>For all outcomes, we carried out analyses, as far as possible, on an intention-to-treat basis, i.e. we attempted to include all participants randomised to each group in the analyses, and all participants analysed in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each trial is the number randomised minus any participants whose outcomes are known to be missing.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-07-12 17:20:04 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed statistical heterogeneity in each meta-analysis using the T², I² and Chi² statistics. We regarded heterogeneity as substantial if the I² was greater than 30% and either the T² was greater than zero, or there was a low P value (less than 0.10) in the Chi² test for heterogeneity.<B> </B>
</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-05-22 13:05:40 +0100" MODIFIED_BY="[Empty name]">
<P>In future updates, if there are 10 or more studies in the meta-analysis we will investigate reporting biases (such as publication bias) using funnel plots. We will assess funnel plot asymmetry visually. If asymmetry is suggested by a visual assessment, we will perform exploratory analyses to investigate it.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-07-12 17:21:33 +0100" MODIFIED_BY="[Empty name]">
<P>We carried out statistical analysis using the Review Manager software (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>). We used fixed-effect meta-analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect: i.e. where trials were examining the same intervention, and the trials&#8217; populations and methods were judged sufficiently similar. If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if substantial statistical heterogeneity was detected, we used random-effects meta-analysis to produce an overall summary if an average treatment effect across trials was considered clinically meaningful. The random-effects summary was treated as the average of the range of possible treatment effects and we discuss the clinical implications of treatment effects differing between trials. If the average treatment effect was not clinically meaningful, we did not combine trials.</P>
<P>If we used random-effects analyses, the results were presented as the average treatment effect with 95% confidence intervals, and the estimates of  T² and I².</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-07-12 17:20:16 +0100" MODIFIED_BY="[Empty name]">
<P>We did not carry out any subgroup analysis in this 2013 update.</P>
<P>In future updates, if we identify substantial heterogeneity, we will investigate it using subgroup analyses and sensitivity analyses. We will consider whether an overall summary is meaningful, and if it is, use random-effects analysis to produce it.</P>
<P>We plan to carry out the following subgroup analyses.</P>
<OL>
<LI>Antithrombotic agent administered (UFH versus LMWH versus other).</LI>
<LI>Gestational age treatment commenced (first trimester versus second trimester versus third trimester). </LI>
</OL>
<P>The primary outcomes will be used in subgroup analysis (perinatal mortality; preterm birth less than 34 weeks' gestation; and major neurodevelopmental delay at childhood follow-up).</P>
<P>We will assess subgroup differences by interaction tests available within RevMan (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>). We will report the results of subgroup analyses quoting the &#967;2 statistic and P value, and the interaction test I² value.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-05-22 13:13:52 +0100" MODIFIED_BY="Sonja L  Henderson">
<P>Sensitivity analyses will be conducted to evaluate the effect of trial quality in future updates.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-07-16 15:50:57 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-07-12 17:20:27 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2013-06-25 14:25:10 +0100" MODIFIED_BY="[Empty name]">
<P>The search of the Pregnancy and Childbirth Group's Trials Register found 22 reports of 15 studies. The original review included five studies, and this updated review has included an additional five studies; for further details, see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. Two studies were excluded (<LINK REF="STD-Airoldi-1988" TYPE="STUDY">Airoldi 1988</LINK>; <LINK REF="STD-Eid-2006" TYPE="STUDY">Eid 2006</LINK>) as they were not randomised (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). Four reports of two studies (<LINK REF="STD-Bonnar-1980" TYPE="STUDY">Bonnar 1980</LINK>; <LINK REF="STD-Ferrier-2000" TYPE="STUDY">Ferrier 2000</LINK>) have been reported in abstract form only, and further information is required to assess their methodological quality and relevance to this review. One further report is also awaiting classification (<LINK REF="STD-Yu-2004b" TYPE="STUDY">Yu 2004b</LINK>) (see <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-07-12 17:20:27 +0100" MODIFIED_BY="[Empty name]">
<P>Our search strategy identified 22 reports of 15 studies for consideration. The original review included five studies (484 women) which met the inclusion criteria (<LINK REF="STD-Kincaid_x002d_Smith-1995" TYPE="STUDY">Kincaid-Smith 1995</LINK>; <LINK REF="STD-Mello-2005" TYPE="STUDY">Mello 2005</LINK>; <LINK REF="STD-Nieder-1995" TYPE="STUDY">Nieder 1995</LINK>; <LINK REF="STD-Rey-2009" TYPE="STUDY">Rey 2009</LINK>; <LINK REF="STD-Yu-2004a" TYPE="STUDY">Yu 2004a</LINK>). The updated review has included a further five studies (<LINK REF="STD-Gris-2010" TYPE="STUDY">Gris 2010</LINK>; <LINK REF="STD-Gris-2011" TYPE="STUDY">Gris 2011</LINK>; <LINK REF="STD-Kingdom-2011" TYPE="STUDY">Kingdom 2011</LINK>; <LINK REF="STD-Martinelli-2012" TYPE="STUDY">Martinelli 2012</LINK>; <LINK REF="STD-Yu-2010" TYPE="STUDY">Yu 2010</LINK>), involving an additional 655 women.</P>
<P>Nine studies compared heparin (alone or in combination with dipyridamole or low-dose aspirin) with no treatment (<LINK REF="STD-Gris-2010" TYPE="STUDY">Gris 2010</LINK>; <LINK REF="STD-Gris-2011" TYPE="STUDY">Gris 2011</LINK>; <LINK REF="STD-Kincaid_x002d_Smith-1995" TYPE="STUDY">Kincaid-Smith 1995</LINK>; <LINK REF="STD-Kingdom-2011" TYPE="STUDY">Kingdom 2011</LINK>; <LINK REF="STD-Martinelli-2012" TYPE="STUDY">Martinelli 2012</LINK>; <LINK REF="STD-Mello-2005" TYPE="STUDY">Mello 2005</LINK>; <LINK REF="STD-Rey-2009" TYPE="STUDY">Rey 2009</LINK>; <LINK REF="STD-Yu-2004a" TYPE="STUDY">Yu 2004a</LINK>; <LINK REF="STD-Yu-2010" TYPE="STUDY">Yu 2010</LINK>). The study by Yu and colleagues involved a comparison between UFH and LMWH also (<LINK REF="STD-Yu-2004a" TYPE="STUDY">Yu 2004a</LINK>). A single study compared trapidil (triazolopyrimidine) with placebo (<LINK REF="STD-Nieder-1995" TYPE="STUDY">Nieder 1995</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Participant population</HEADING>
<P>The included studies recruited women considered to be at particularly high risk of adverse outcomes from placental insufficiency, predominantly based on a past history (particularly pre-eclampsia, eclampsia, renal disease, placental abruption, fetal growth restriction, or fetal death).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Reported outcomes</HEADING>
<P>There was variable reporting of the pre-specified outcomes.</P>
<P>Refer to <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> for further information.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2012-08-31 02:19:38 +0100" MODIFIED_BY="Denise Atherton">
<P>Two studies were excluded (<LINK REF="STD-Airoldi-1988" TYPE="STUDY">Airoldi 1988</LINK>; <LINK REF="STD-Eid-2006" TYPE="STUDY">Eid 2006</LINK>) as they were not randomised (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-07-16 15:50:57 +0100" MODIFIED_BY="[Empty name]">
<P>The overall quality of the included trials was considered fair to good.</P>
<P>Please refer to the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> for further details and <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<ALLOCATION MODIFIED="2013-07-16 15:50:57 +0100" MODIFIED_BY="Denise Atherton">
<P>All trials were stated to be randomised, with <LINK REF="STD-Gris-2010" TYPE="STUDY">Gris 2010</LINK>, <LINK REF="STD-Gris-2011" TYPE="STUDY">Gris 2011</LINK>, <LINK REF="STD-Kingdom-2011" TYPE="STUDY">Kingdom 2011</LINK>, <LINK REF="STD-Martinelli-2012" TYPE="STUDY">Martinelli 2012</LINK>, <LINK REF="STD-Mello-2005" TYPE="STUDY">Mello 2005</LINK> and <LINK REF="STD-Rey-2009" TYPE="STUDY">Rey 2009</LINK> utilising computer-generated random number tables. The precise method of randomisation was unclear or not stated in <LINK REF="STD-Kincaid_x002d_Smith-1995" TYPE="STUDY">Kincaid-Smith 1995</LINK>, <LINK REF="STD-Nieder-1995" TYPE="STUDY">Nieder 1995</LINK>, <LINK REF="STD-Yu-2004a" TYPE="STUDY">Yu 2004a</LINK> and <LINK REF="STD-Yu-2010" TYPE="STUDY">Yu 2010</LINK>. Allocation concealment utilised a central telephone randomisation service in <LINK REF="STD-Kingdom-2011" TYPE="STUDY">Kingdom 2011</LINK> and <LINK REF="STD-Martinelli-2012" TYPE="STUDY">Martinelli 2012</LINK>, while sealed opaque envelopes were utilised by <LINK REF="STD-Gris-2010" TYPE="STUDY">Gris 2010</LINK>, <LINK REF="STD-Gris-2011" TYPE="STUDY">Gris 2011</LINK>, <LINK REF="STD-Kincaid_x002d_Smith-1995" TYPE="STUDY">Kincaid-Smith 1995</LINK> and <LINK REF="STD-Rey-2009" TYPE="STUDY">Rey 2009</LINK>. The method of allocation concealment was unclear or not stated for <LINK REF="STD-Mello-2005" TYPE="STUDY">Mello 2005</LINK>, <LINK REF="STD-Nieder-1995" TYPE="STUDY">Nieder 1995</LINK>, <LINK REF="STD-Yu-2004a" TYPE="STUDY">Yu 2004a</LINK>, and <LINK REF="STD-Yu-2010" TYPE="STUDY">Yu 2010</LINK>.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-06-25 14:24:22 +0100" MODIFIED_BY="Denise Atherton">
<P>The study by <LINK REF="STD-Rey-2009" TYPE="STUDY">Rey 2009</LINK> was the only one to ensure blinding of outcome assessors; blinding of participants and caregivers was not achieved or not stated in any of the included trials (<LINK REF="STD-Gris-2010" TYPE="STUDY">Gris 2010</LINK>; <LINK REF="STD-Gris-2011" TYPE="STUDY">Gris 2011</LINK>; <LINK REF="STD-Kingdom-2011" TYPE="STUDY">Kingdom 2011</LINK>; <LINK REF="STD-Kincaid_x002d_Smith-1995" TYPE="STUDY">Kincaid-Smith 1995</LINK>; <LINK REF="STD-Martinelli-2012" TYPE="STUDY">Martinelli 2012</LINK>; <LINK REF="STD-Mello-2005" TYPE="STUDY">Mello 2005</LINK>; <LINK REF="STD-Nieder-1995" TYPE="STUDY">Nieder 1995</LINK>; <LINK REF="STD-Rey-2009" TYPE="STUDY">Rey 2009</LINK>; <LINK REF="STD-Yu-2004a" TYPE="STUDY">Yu 2004a</LINK>; <LINK REF="STD-Yu-2010" TYPE="STUDY">Yu 2010</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-05-21 16:51:12 +0100" MODIFIED_BY="Denise Atherton">
<P>The majority of the studies appeared to be at low risk of attrition bias, with low levels of missing data.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-05-21 16:52:22 +0100" MODIFIED_BY="Denise Atherton">
<P>The majority of the studies appeared to be at low risk of selective reporting, although without access to a pre-specified trial protocol, this is difficult to assess.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-06-18 12:19:39 +0100" MODIFIED_BY="Denise Atherton">
<P>The baseline characteristics of participants in the included studies appeared comparable at the time of trial entry. However, the trials by <LINK REF="STD-Martinelli-2012" TYPE="STUDY">Martinelli 2012</LINK> and <LINK REF="STD-Rey-2009" TYPE="STUDY">Rey 2009</LINK> were both halted prior to achieving their intended sample size for reasons of slow recruitment and futility.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-07-12 17:20:44 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Heparin (alone or with other medications) versus no treatment</HEADING>
<P>We included nine studies involving 979 women.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>For the primary outcomes, women who were administered heparin during pregnancy were at significantly lower risk of perinatal death (six studies; 653 women; risk ratio (RR) 0.40; 95% confidence intervals (CI) 0.20 to 0.78; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), or of giving birth prior to 34 weeks' gestation (three studies; 494 women; RR 0.46; 95% CI 0.29 to 0.73; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). There was no available information for the outcome major neurodevelopmental delay at child follow-up (one study; 107 infants; RR not estimable).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>Women administered heparin during pregnancy were at significantly lower risk of developing pre-eclampsia (seven studies; 761 women; RR 0.43; 95% CI 0.28 to 0.65). However a high degree of heterogeneity was identified, and when a random-effects model was used, the results were no longer statistically significant (seven studies; 761 women; average RR 0.47; 95% CI 0.22 to 1.03; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>; random-effects model; Heterogeneity: Tau² = 0.58; Chi² = 14.24, df = 6 (P = 0.03); I² = 58%). The use of heparin was not associated with a significant reduction in eclampsia (one study; 135 women; RR not estimable; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). While the use of heparin was associated with a significant difference in mean length of antenatal hospitalisation (one study; 20 women; mean difference (days) (MD) -9.00; 95% CI -15.14 to -2.86; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>), and birth prior to 37 weeks' gestation (five studies; 621 women; RR 0.72; 95% CI 0.58 to 0.90; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>), there were no significant differences in the risk of placental abruption (four studies; 551 women; RR 0.38; 95% CI 0.10 to 1.40; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
<P>Infants born to women following heparin administration were significantly less likely to have birthweight below the 10th centile (seven studies; 710 infants; RR 0.41; 95% CI 0.27 to 0.61; <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>), and Apgar score of less than seven at five minutes of age (three studies; 519 infants; RR 0.42; 95% CI 0.29 to 0.60; <LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>). Infants were less likely to require admission to the neonatal intensive care unit (three studies; 416 infants; RR 0.53; 95% CI 0.35 to 0.79), although a high degree of heterogeneity was identified, and when a random-effects model was used, the results were no longer statistically significant (three studies; 416 infants; average RR 0.62; 95% CI 0.25 to 1.53; <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>; random-effects model; Heterogeneity: Tau² = 0.51; Chi² = 9.85, df = 2 (P = 0.007); I² = 80%). There were no statistically significant differences identified in risk of either intrauterine fetal death (three studies; 519 women; RR 0.58; 95% CI 0.23 to 1.46; <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>), or neonatal death (two studies; 384 infants; RR 0.29; 95% CI 0.06 to 1.36; <LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Triazolopyrimadine versus placebo</HEADING>
<P>We included a single study involving 160 women at risk of developing pre-eclampsia.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>None of the pre-specified primary outcomes were reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>There were no statistically significant differences identified for the outcome pre-eclampsia (one study; 160 women; RR 0.38; 95% CI 0.12 to 1.16; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Unfractionated heparin versus low molecular weight heparin</HEADING>
<P>We included a single study involving 68 women with established fetal growth restriction.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>There was no available information for the outcome major neurodevelopmental delay at child follow-up (one study; 68 infants; RR not estimable; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>There was no available information for the outcomes antepartum haemorrhage or thrombocytopaenia (one study; 68 infants; RR not estimable; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>; <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). There were no statistically significant differences identified for the outcomes preterm birth before 37 weeks' gestation (one study; 68 women; RR 1.26; 95% CI 0.22 to 7.05; <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>), or infant birthweight less than the 10th centile (one study; 68 infants; RR 0.84; 95% CI 0.13 to 5.61; <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-07-12 17:21:06 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2013-06-14 12:28:40 +0100" MODIFIED_BY="Denise Atherton">
<P>This review identified a statistically significant reduction in risk of perinatal mortality, preterm birth before 34 and 37 weeks' gestation, and infant birthweight below the 10th centile for gestational age, when comparing antenatal heparin administration with no treatment for women considered at to be at particularly high risk of adverse outcomes and placental dysfunction.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-07-12 17:21:06 +0100" MODIFIED_BY="Denise Atherton">
<P>The findings of this review are based on 10 included randomised studies and 1139 participants. However, for the majority of outcomes, the available meta-analysis involved a smaller number of studies and participants (ranging from 20 to 710). This review identified a statistically significant reduction in risk of perinatal mortality, preterm birth before 34 and 37 weeks' gestation, and infant birthweight below the 10th centile for gestational age. The effect of treatment with antithrombotic agents on a woman's risk of pre-eclampsia and eclampsia remain uncertain, with considerable heterogeneity across the identified trials to date, reflecting differences in the included patient populations. There is a lack of reliable information available related to clinically relevant infant health outcomes, which have not been reported to date, including childhood growth and development. Similarly, there is a lack of information available related to maternal side effects from medication, and maternal psychological wellbeing associated with prolonged daily treatment during pregnancy.</P>
<P>The proposed mechanism whereby heparin mediates beneficial effects on maternal and perinatal outcome is based on the assumption that heparin is a placental anticoagulant. However, to date only one trial (<LINK REF="STD-Kingdom-2011" TYPE="STUDY">Kingdom 2011</LINK>) has incorporated placental pathology analysis, noting no differences in the prevalence of placental infarction between women exposed to heparin during pregnancy and women who were not. Any subsequent trials evaluating the role of heparin in women with evidence of placental dysfunction are encouraged to incorporate placental pathology assessments blinded to treatment allocation.</P>
<P>Heparin appears to reduce the risk of developing pre-eclampsia. In-vitro, heparin effectively reverses the anti-angiogenic response of placenta villi (<LINK REF="REF-Sobel-2011" TYPE="REFERENCE">Sobel 2011</LINK>). Severe forms of pre-eclampsia are associated with increased circulating levels of the anti-angiogenic protein sFlt1 and reduced levels of placenta growth factor (PlGF) (<LINK REF="REF-Rana-2012" TYPE="REFERENCE">Rana 2012</LINK>). It is of concern therefore that heparin increases placental production of sFlt-1, and thus circulating levels during pregnancy (<LINK REF="REF-Drewlo-2011" TYPE="REFERENCE">Drewlo 2011</LINK>). Further research is therefore required to understand the interactions between heparin and the placenta that mediate a reduction in the risk of developing severe pre-eclampsia.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-07-12 17:21:06 +0100" MODIFIED_BY="Denise Atherton">
<P>The overall quality of the included trials was considered fair to good. All trials were stated to be randomised, with six utilising computer-generated random number tables. Two trials utilised a central telephone randomisation service to maintain allocation concealment, while four trials used sealed opaque envelopes. Blinding of outcome assessors was achieved in one trial only, with the remainder either not stating or not achieving blinding of participants or caregivers, increasing the potential for bias. While there did not appear to be evidence of selective reporting or incomplete data, two trials were halted prior to achieving their estimated sample size due to reasons of difficulties with recruitment and futility.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-06-18 12:25:22 +0100" MODIFIED_BY="Denise Atherton">
<P>Methodologically, six of the 10 included trials were considered to be at low risk of bias. However, blinding of outcome assessors was achieved in only one study, and participants and caregivers were aware of treatment allocation in all of the included studies.</P>
</POTENTIAL_BIASES>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-06-14 12:28:45 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-06-14 12:28:45 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment with heparin for women considered at particularly high risk of adverse pregnancy complications secondary to placental insufficiency was associated with a statistically significant reduction in risk of perinatal mortality, preterm birth before 34 and 37 weeks' gestation, and infant birthweight below the 10th centile for gestational age, when compared with no treatment. However, important information about infant and long-term childhood growth and development is currently unavailable. Furthermore, the interpretation of these findings and potential clinical use of heparin should be confined to women who are considered to be at particularly high risk of adverse pregnancy outcomes, often based on past pregnancy history.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-05-01 06:37:50 +0100" MODIFIED_BY="[Empty name]">
<P>Further well designed randomised trials that are sufficiently powered to detect differences in important maternal outcomes (including both pre-eclampsia and eclampsia, as well as potential complications from antithrombotic medications), and infant and childhood growth and neurodevelopmental outcomes are required, with standardised reporting of outcomes.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-06-18 12:26:04 +0100" MODIFIED_BY="[Empty name]">
<P>As part of the pre-publication editorial process, this review has been commented on by three peers (an editor and two referees who are external to the editorial team) and the Group's Statistical Adviser.</P>
<P>The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Pregnancy and Childbirth Group.  The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, NHS or the Department of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-06-18 12:26:27 +0100" MODIFIED_BY="[Empty name]">
<P>John Kingdom, Jodie Dodd, Anne McLeod and Rory Windrim are authors of one of the included studies (<LINK REF="STD-Kingdom-2011" TYPE="STUDY">Kingdom 2011</LINK>). This trial assessment and data extraction was conducted by an independent assessor, with experience in the conduct of Cochrane systematic reviews.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-07-17 13:17:55 +0100" MODIFIED_BY="[Empty name]">
<P>J Dodd prepared this updated review. J Dodd and R Windrim assessed studies for inclusion and conducted data extraction. All review authors reviewed and commented critically on all versions of the updated review and agreed to the final version submitted.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-07-17 14:51:29 +0100" MODIFIED_BY="[Empty name]">
<P>Methods updated to current Cochrane Pregnancy and Childbirth Group standards. </P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-07-12 17:39:04 +0100" MODIFIED_BY="Lynn Hampson">
<STUDIES MODIFIED="2013-07-12 15:21:48 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-07-12 15:19:31 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Gris-2010" MODIFIED="2012-08-29 03:35:37 +0100" MODIFIED_BY="[Empty name]" NAME="Gris 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-29 03:35:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Gris JC, Chauleur C, Faillie JL, Baer G, Mares P, Fabbro-Peray P, et al</AU>
<TI>Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae: the pilot randomised controlled NOH-AP trial</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2010</YR>
<VL>104</VL>
<NO>4</NO>
<PG>771-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gris-2011" MODIFIED="2012-08-29 03:35:41 +0100" MODIFIED_BY="[Empty name]" NAME="Gris 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-29 03:35:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gris JC, Chauleur C, Molinari N, Mares P, Fabbro-Peray P, Quere I, et al</AU>
<TI>Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia: The pilot randomised controlled NOH-PE trial</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2011</YR>
<VL>106</VL>
<NO>6</NO>
<PG>1053-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kincaid_x002d_Smith-1995" MODIFIED="2009-09-29 12:04:19 +0100" MODIFIED_BY="[Empty name]" NAME="Kincaid-Smith 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-09-29 12:03:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kincaid Smith P, North RA, Fairley KF, Kloss M, Ihle BU</AU>
<TI>Prevention of pre-eclampsia in high risk women with renal disease: a prospective randomized trial of heparin and dipyridamole</TI>
<SO>Nephrology</SO>
<YR>1995</YR>
<VL>1</VL>
<PG>297-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-09-17 04:15:38 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kingdom-2011" MODIFIED="2013-07-12 15:19:31 +0100" MODIFIED_BY="[Empty name]" NAME="Kingdom 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-05-22 11:54:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Kingdom J D Current</AU>
<TI>Does heparin improve pregnancy outcomes for women with evidence of placental dysfunction?</TI>
<SO>Controlled Trials (www.controlled-trials.com)</SO>
<YR>(accessed 21 June 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-12 15:19:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kingdom JCP, Walker M, Proctor LK, Keating S, Shah PS, McLeod A, et al</AU>
<TI>Unfractionated heparin for second trimester placental insufficiency: A pilot randomized trial</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2011</YR>
<VL>9</VL>
<NO>8</NO>
<PG>1483-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-22 11:50:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walker M, Proctor L, Dodd J, Keunen H, Keating S, McLeod A, et al</AU>
<TI>Heparin to prevent placental insufficiency (HEPRIN): A pilot randomized controlled trial</TI>
<SO>Reproductive Sciences</SO>
<YR>2011</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>361A-2A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martinelli-2012" MODIFIED="2012-08-29 03:35:49 +0100" MODIFIED_BY="[Empty name]" NAME="Martinelli 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-08-29 03:35:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Martinelli I, Ruggenenti P, Cetin I, Pardi G, Perna A, Vergani P, et al</AU>
<TI>Heparin in pregnant women with previous placenta-mediated pregnancy complications: A prospective, randomized, multicenter, controlled clinical trial</TI>
<SO>Blood</SO>
<YR>2012</YR>
<VL>119</VL>
<NO>14</NO>
<PG>3269-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-29 03:35:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martinelli I</AU>
<TI>Low molecular weight heparin in pregnant women with previous obstetrical complications. A multicenter, randomized trial</TI>
<SO>Pathophysiology of Haemostasis and Thrombosis</SO>
<YR>2010</YR>
<VL>37 Suppl 1</VL>
<PG>A3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mello-2005" MODIFIED="2009-09-29 12:04:42 +0100" MODIFIED_BY="[Empty name]" NAME="Mello 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-09-29 12:03:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mello G, Parretti E, Fatini C, Riviello C, Gensini F, Marchionni M, et al</AU>
<TI>Efficacy of LMWH in lowering the recurrence rate of preeclampsia and in restoring the physiological vascular changes in ACE DD genotype women [abstract]</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>Suppl 1</NO>
<PG>162</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-09-29 12:04:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mello G, Parretti E, Fatini C, Riviello C, Gensini F, Marchionni M, et al</AU>
<TI>Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women</TI>
<SO>Hypertension</SO>
<YR>2005</YR>
<VL>45</VL>
<NO>1</NO>
<PG>86-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nieder-1995" MODIFIED="2009-09-29 12:03:54 +0100" MODIFIED_BY="[Empty name]" NAME="Nieder 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-09-29 12:03:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nieder J, Claus P, Augustin W</AU>
<TI>Prevention of pre-eclampsia and fetal growth retardation by trapidil</TI>
<SO>Zentralblatt fur Gynakologie</SO>
<YR>1995</YR>
<VL>117</VL>
<PG>23-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rey-2009" MODIFIED="2009-09-29 12:06:13 +0100" MODIFIED_BY="[Empty name]" NAME="Rey 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-09-29 12:06:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rey E, Garneau P, David M, Gauthier R, Leduc L, Michon N, et al</AU>
<TI>Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2009</YR>
<VL>7</VL>
<NO>1</NO>
<PG>58-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-09-29 12:03:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rey E</AU>
<TI>Dalteparin in prevention of recurrence of severe obstetrical complications in women without thrombophilia</TI>
<SO>JOGC: Journal of Obstetrics and Gynaecology Canada</SO>
<YR>2007</YR>
<VL>29</VL>
<NO>6 Suppl 1</NO>
<PG>S46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-2004a" MODIFIED="2013-06-25 14:24:22 +0100" MODIFIED_BY="[Empty name]" NAME="Yu 2004a" YEAR="2004">
<REFERENCE MODIFIED="2009-09-29 12:03:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu YH, Shen LY, Zhong M, Zhang Y, Su GD, Gao YF, et al</AU>
<TI>Effect of heparin on fetal growth restriction</TI>
<SO>Chung-Hua Fu Chan Ko Tsa Chih</SO>
<YR>2004</YR>
<VL>39</VL>
<NO>12</NO>
<PG>793-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-2010" MODIFIED="2012-08-29 03:35:58 +0100" MODIFIED_BY="[Empty name]" NAME="Yu 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-29 03:35:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu YH, Shen LY, Zou H, Wang ZJ, Gong SP</AU>
<TI>Heparin for patients with growth restricted fetus: a prospective randomized controlled trial</TI>
<SO>Journal of Maternal-Fetal and Neonatal Medicine</SO>
<YR>2010</YR>
<VL>23</VL>
<NO>9</NO>
<PG>980-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-08-31 02:02:45 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Airoldi-1988" MODIFIED="2012-08-31 02:02:40 +0100" MODIFIED_BY="[Empty name]" NAME="Airoldi 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-08-31 02:02:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Airoldi ML, Capetta P, Tasca A, Bertulessi C, Rossi E, Polvani F</AU>
<TI>Role of early treatment with heparin and dipyridamole in the prevention of pre-eclampsia and placental insufficiency</TI>
<SO>6th International Congress of the International Society for the Study of Hypertension in Pregnancy; 1988 May 22-26; Montreal, Quebec, Canada</SO>
<YR>1988</YR>
<PG>233</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eid-2006" MODIFIED="2012-08-31 02:02:45 +0100" MODIFIED_BY="[Empty name]" NAME="Eid 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-08-31 02:02:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eid M, Taye A</AU>
<TI>Tinzaparin sodium supplementation improves the obstetric outcomes in singleton gestations following ART</TI>
<SO>Human Reproduction</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>Suppl</NO>
<PG>i70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-07-12 15:21:48 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bonnar-1980" MODIFIED="2013-07-12 15:21:48 +0100" MODIFIED_BY="[Empty name]" NAME="Bonnar 1980" YEAR="1980">
<REFERENCE MODIFIED="2013-07-12 15:21:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Bonnar J, Gitt BP</AU>
<TI>Prevention of fetal growth retardation by antithrombotic therapy</TI>
<SO>2nd Congress of the International Society for the Study of Hypertension in Pregnancy; 1980 Dec 1-4; Cairo Egypt</SO>
<YR>1980</YR>
<PG>60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-09-29 12:09:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gill BP, Bonnar J</AU>
<TI>Controlled study of subcutaneous heparin and dipyridamole in women at risk to fetal growth retardation</TI>
<SO>1st Congress of the International Society of Hypertension in Pregnancy; 1978 September 27-29; Dublin, Ireland</SO>
<YR>1978</YR>
<PG>97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferrier-2000" MODIFIED="2009-09-29 12:03:38 +0100" MODIFIED_BY="[Empty name]" NAME="Ferrier 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-09-29 12:03:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferrier C, Koeferl U, Duerig P, Schneider H</AU>
<TI>Effects of LMW-heparin and low-dose aspirin on renal uric acid handling in high-risk pregnancies</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>Suppl 1</NO>
<PG>O68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-09-29 12:03:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferrier C, Koferl U, Durig P, Schneider H</AU>
<TI>LMW-heparin and low-dose aspirin for prevention of preeclampsia: preliminary data of a randomized prospective study [abstract]</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>1</NO>
<PG>82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-2004b" MODIFIED="2013-06-25 14:24:09 +0100" MODIFIED_BY="[Empty name]" NAME="Yu 2004b" YEAR="2004">
<REFERENCE MODIFIED="2012-07-17 22:36:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Yu YH, Shen LY, Wang ZJ, Zhang Y, Su GD</AU>
<TI>[Effect of heparin on umbilical blood flow in patients with fetal growth retardation]. [Chinese]</TI>
<SO>Di Yi Junyi Daxue Xuebao</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>4</NO>
<PG>423-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2013-05-01 05:52:17 +0100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-07-12 17:39:04 +0100" MODIFIED_BY="Lynn Hampson">
<ADDITIONAL_REFERENCES MODIFIED="2013-07-12 17:39:04 +0100" MODIFIED_BY="Lynn Hampson">
<REFERENCE ID="REF-Alkazaleh-2004" MODIFIED="2009-09-29 14:23:46 +0100" MODIFIED_BY="Jill V Hampson" NAME="Alkazaleh 2004" TYPE="JOURNAL_ARTICLE">
<AU>Alkazaleh F, Viero S, Simchen M, Walker M, Smith G, Laskin C, et al</AU>
<TI>Ultrasound diagnosis of severe thrombotic placental damage in the second trimester: an observational study</TI>
<SO>Ultrasound in Obstetrics and Gynecology</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>5</NO>
<PG>472-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bernstein-2000" MODIFIED="2009-09-29 12:43:50 +0100" MODIFIED_BY="Jill V Hampson" NAME="Bernstein 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bernstein IM, Horbar JD, Badger GJ, Ohlsson A, Golan A, for the Vermont Oxford Network</AU>
<TI>Morbidity and mortality among very-low-birth-weight neonates with intrauterine growth restriction</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2000</YR>
<VL>182</VL>
<NO>1</NO>
<PG>198-206</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bonnar-1975" MODIFIED="2009-09-29 12:44:31 +0100" MODIFIED_BY="Jill V Hampson" NAME="Bonnar 1975" TYPE="JOURNAL_ARTICLE">
<AU>Bonnar J, Redman CW, Sheppard BL</AU>
<TI>Treatment of fetal growth retardation in utero with heparin and dipyridamole</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>1975</YR>
<VL>5</VL>
<NO>1-2</NO>
<PG>123-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burton-2009" MODIFIED="2012-09-22 18:16:50 +0100" MODIFIED_BY="[Empty name]" NAME="Burton 2009" TYPE="JOURNAL_ARTICLE">
<AU>Burton GJ, Woods AW, Jauniaux E, Kingdom JC</AU>
<TI>Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy</TI>
<SO>Placenta</SO>
<YR>2009</YR>
<VL>30</VL>
<NO>6</NO>
<PG>473-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Buyse-1974" MODIFIED="2009-09-29 12:46:35 +0100" MODIFIED_BY="Jill V Hampson" NAME="Buyse 1974" TYPE="JOURNAL_ARTICLE">
<AU>Buyse FG, Wormgoor BH, Bernard JT, Koudstaal J</AU>
<TI>Anticoagulant therapy of patients with repeated placental infarction</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1974</YR>
<VL>43</VL>
<NO>6</NO>
<PG>844-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chupin-1978" MODIFIED="2009-09-29 12:45:37 +0100" MODIFIED_BY="Jill V Hampson" NAME="Chupin 1978" TYPE="JOURNAL_ARTICLE">
<AU>Chupin L, Herrmann JM, Maillet R, Gillet JY, Colette C, Gibey R, et al</AU>
<TI>The effects of heparin in underdevelopment of the fetus due to maternal vascular conditions</TI>
<SO>Journal de Gynecologie, Obstetrique et Biologie de la Reproduction</SO>
<YR>1978</YR>
<VL>7</VL>
<NO>4</NO>
<PG>849-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cnattingius-1998" MODIFIED="2009-09-29 14:04:31 +0100" MODIFIED_BY="Jill V Hampson" NAME="Cnattingius 1998" TYPE="JOURNAL_ARTICLE">
<AU>Cnattingius S, Haglund B, Kramer MS</AU>
<TI>Differences in late fetal death rates in association with determinants of small for gestational age fetuses: population based cohort study</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>316</VL>
<PG>1483-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2001" MODIFIED="2013-07-12 15:27:21 +0100" MODIFIED_BY="Heather Maxwell" NAME="Deeks 2001" TYPE="BOOK_SECTION">
<AU>Deeks JJ, Altman DG, Bradburn MJ</AU>
<TI>Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis</TI>
<SO>Systematic Reviews in Health Care: Meta-analysis in Context</SO>
<YR>2001</YR>
<ED>Egger M, Davey Smith G, Altman DG</ED>
<PB>BMJ Books</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dekker-2001" NAME="Dekker 2001" TYPE="JOURNAL_ARTICLE">
<AU>Dekker G, Sibai B</AU>
<TI>Primary, secondary, and tertiary prevention of pre-eclampsia</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<NO>9251</NO>
<PG>209-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dekker-2005a" NAME="Dekker 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Dekker G</AU>
<TI>Prothrombotic mechanisms in preeclampsia</TI>
<SO>Thrombosis Research</SO>
<YR>2005</YR>
<VL>115</VL>
<PG>17-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dekker-2005b" MODIFIED="2009-09-29 14:10:05 +0100" MODIFIED_BY="Jill V Hampson" NAME="Dekker 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Dekker GA, Robillard PY</AU>
<TI>Preeclampsia: a couple's disease with maternal and fetal manifestations</TI>
<SO>Current Pharmaceutical Design</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>6</NO>
<PG>699-710</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Drewlo-2011" MODIFIED="2013-06-24 16:34:13 +0100" MODIFIED_BY="[Empty name]" NAME="Drewlo 2011" TYPE="JOURNAL_ARTICLE">
<AU>Drewlo S, Levytska K, Sobel M, Baczyk D, Lye SJ, Kingdom JC</AU>
<TI>Heparin promotes soluble VEGF receptor expression in human placental villi to impair endothelial VEGF signaling</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2011</YR>
<VL>9</VL>
<NO>12</NO>
<PG>2486-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egbor-2006" NAME="Egbor 2006" TYPE="JOURNAL_ARTICLE">
<AU>Egbor M, Ansari T, Morris N, Green CJ, Sibbons PD</AU>
<TI>Morphometric placental villous and vascular abnormalities in early- and late-onset pre-eclampsia with and without fetal growth restriction</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2006</YR>
<VL>113</VL>
<NO>5</NO>
<PG>580-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Empson-2005" MODIFIED="2009-09-29 14:16:12 +0100" MODIFIED_BY="Jill V Hampson" NAME="Empson 2005" TYPE="COCHRANE_REVIEW">
<AU>Empson M, Lassere M, Craig J, Scott J</AU>
<TI>Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2009-09-29 14:16:11 +0100" MODIFIED_BY="Jill V Hampson">
<IDENTIFIER MODIFIED="2009-09-29 14:16:11 +0100" MODIFIED_BY="Jill V Hampson" TYPE="DOI" VALUE="10.1002/14651858.CD002859.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ferrazzi-1999" MODIFIED="2009-09-29 14:17:25 +0100" MODIFIED_BY="Jill V Hampson" NAME="Ferrazzi 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ferrazzi E, Bulfamante G, Mezzopane R, Barbera A, Ghidini A, Pardi G</AU>
<TI>Uterine Doppler velocimetry and placental hypoxic-ischemic lesion in pregnancies with fetal intrauterine growth restriction</TI>
<SO>Placenta</SO>
<YR>1999</YR>
<VL>20</VL>
<NO>5-6</NO>
<PG>389-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Franco-2011" MODIFIED="2013-06-24 16:39:43 +0100" MODIFIED_BY="[Empty name]" NAME="Franco 2011" TYPE="JOURNAL_ARTICLE">
<AU>Franco C, Walker M, Robertson J, Fitzgerald B, Keating S, McLeod A, et al</AU>
<TI>Placental infarction and thrombophilia</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>2011</YR>
<VL>117</VL>
<NO>4</NO>
<PG>929-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fuke-1994" NAME="Fuke 1994" TYPE="JOURNAL_ARTICLE">
<AU>Fuke Y, Aono T, Imai S, Suehara N, Fujita T, Nakayama M</AU>
<TI>Clinical significance and treatment of massive intervillous fibrin deposition associated with recurrent fetal growth retardation</TI>
<SO>Gynecologic and Obstetric Investigation</SO>
<YR>1994</YR>
<VL>38</VL>
<NO>1</NO>
<PG>5-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gates-2002" MODIFIED="2009-09-29 12:19:48 +0100" MODIFIED_BY="[Empty name]" NAME="Gates 2002" TYPE="COCHRANE_REVIEW">
<AU>Gates S, Brocklehurst P, Davis LJ</AU>
<TI>Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2009-09-29 12:19:48 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-09-29 12:19:48 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001689"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Greer-2006" NAME="Greer 2006" TYPE="JOURNAL_ARTICLE">
<AU>Greer IA</AU>
<TI>Anticoagulants in pregnancy</TI>
<SO>Journal of Thrombosis and Thrombolysis</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>1</NO>
<PG>57-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-09-29 14:24:53 +0100" MODIFIED_BY="Jill V Hampson" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-08-28 11:43:36 +0100" MODIFIED_BY="Denise Atherton" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaandorp-2009" MODIFIED="2009-09-29 14:45:47 +0100" MODIFIED_BY="Jill V Hampson" NAME="Kaandorp 2009" TYPE="COCHRANE_REVIEW">
<AU>Kaandorp S, Di Nisio M, Goddijn M, Middeldorp S</AU>
<TI>Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-09-29 14:45:47 +0100" MODIFIED_BY="Jill V Hampson">
<IDENTIFIER MODIFIED="2009-09-29 14:45:47 +0100" MODIFIED_BY="Jill V Hampson" TYPE="DOI" VALUE="10.1002/14651858.CD004734.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Khong-2004" NAME="Khong 2004" TYPE="JOURNAL_ARTICLE">
<AU>Khong TY</AU>
<TI>Placental vascular development and neonatal outcome</TI>
<SO>Seminars in Neonatology</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>4</NO>
<PG>255-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kok-1998" MODIFIED="2009-09-29 14:26:36 +0100" MODIFIED_BY="Jill V Hampson" NAME="Kok 1998" TYPE="JOURNAL_ARTICLE">
<AU>Kok JH, Den Ouden AL, Verloove-Vanhorick SP, Brand R</AU>
<TI>Outcome of very preterm small for gestational age infants: the first nine years of life</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>1998</YR>
<VL>105</VL>
<NO>2</NO>
<PG>162-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Laws-2004" NAME="Laws 2004" TYPE="BOOK">
<AU>Laws PJ, Sullivan EA</AU>
<SO>Australia's mothers and babies, 2002</SO>
<YR>2004</YR>
<PB>Australian Institute of Health and Welfare, National Perinatal Statistics Unit</PB>
<CY>Sydney</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McIntire-1999" MODIFIED="2009-09-29 14:28:25 +0100" MODIFIED_BY="Jill V Hampson" NAME="McIntire 1999" TYPE="JOURNAL_ARTICLE">
<AU>McIntire DD, Bloom SL, Casey BM, Leveno KJ</AU>
<TI>Birth weight in relation to morbidity and mortality among newborn infants</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>340</VL>
<NO>16</NO>
<PG>1234-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moe-1982" NAME="Moe 1982" TYPE="JOURNAL_ARTICLE">
<AU>Moe N</AU>
<TI>Anticoagulant therapy in the prevention of placental infarction and perinatal death</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1982</YR>
<VL>59</VL>
<NO>4</NO>
<PG>481-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rana-2012" MODIFIED="2013-06-24 16:36:01 +0100" MODIFIED_BY="[Empty name]" NAME="Rana 2012" TYPE="JOURNAL_ARTICLE">
<AU>Rana S, Hacker MR, Modest AM, Salahuddin S, Lim KH, Verlohren S, et al</AU>
<TI>Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia</TI>
<SO>Hypertension</SO>
<YR>2012</YR>
<VL>60</VL>
<NO>2</NO>
<PG>451-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2010-04-23 11:07:06 +0100" MODIFIED_BY="Lynn Hampson" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2012-08-28 11:43:45 +0100" MODIFIED_BY="Denise Atherton" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robson-2002" NAME="Robson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Robson SC, Simpson H, Ball E, Lyall F, Bulmer JN</AU>
<TI>Punch biopsy of the human placental bed</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2002</YR>
<VL>187</VL>
<NO>5</NO>
<PG>1349-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roth-1999" MODIFIED="2009-09-29 14:30:18 +0100" MODIFIED_BY="Jill V Hampson" NAME="Roth 1999" TYPE="JOURNAL_ARTICLE">
<AU>Roth S, Chang TC, Robson S, Spencer JA, Wyatt JS, Stewart AL</AU>
<TI>The neurodevelopmental outcome of term infants with different intrauterine growth characteristics</TI>
<SO>Early Human Development</SO>
<YR>1999</YR>
<VL>55</VL>
<NO>1</NO>
<PG>39-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sander-2005" MODIFIED="2009-09-29 14:32:27 +0100" MODIFIED_BY="Jill V Hampson" NAME="Sander 2005" TYPE="JOURNAL_ARTICLE">
<AU>Sander CM, Gilliland D, Richardson A, Foley KM, Fredericks J</AU>
<TI>Stillbirths with placental hemorrhagic endovasculitis: a morphologic assessment with clinical implications</TI>
<SO>Archives of Pathology and Laboratory Medicine</SO>
<YR>2005</YR>
<VL>129</VL>
<NO>5</NO>
<PG>632-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sibai-2005" MODIFIED="2009-09-29 14:33:18 +0100" MODIFIED_BY="Jill V Hampson" NAME="Sibai 2005" TYPE="JOURNAL_ARTICLE">
<AU>Sibai B, Dekker G, Kupferminc M</AU>
<TI>Pre-eclampsia</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>365</VL>
<NO>9461</NO>
<PG>785-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sobel-2011" MODIFIED="2013-06-24 16:36:52 +0100" MODIFIED_BY="[Empty name]" NAME="Sobel 2011" TYPE="JOURNAL_ARTICLE">
<AU>Sobel ML, Kingdom J, Drewlo S</AU>
<TI>Angiogenic response of placental villi to heparin</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>2011</YR>
<VL>117</VL>
<NO>6</NO>
<PG>1375-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tan-2005" NAME="Tan 2005" TYPE="JOURNAL_ARTICLE">
<AU>Tan TY, Yeo GS</AU>
<TI>Intrauterine growth restriction</TI>
<SO>Current Opinion in Obstetrics and Gynecology</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>2</NO>
<PG>135-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Toal-2008" MODIFIED="2009-09-29 14:37:33 +0100" MODIFIED_BY="Jill V Hampson" NAME="Toal 2008" TYPE="JOURNAL_ARTICLE">
<AU>Toal M, Keating S, Machin G, Dodd J, Adamson SL, Windrim RC, et al</AU>
<TI>Determinants of adverse perinatal outcome in high-risk women with abnormal uterine artery Doppler images</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2008</YR>
<VL>198</VL>
<NO>3</NO>
<PG>330.e1-330.e7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Viero-2004" MODIFIED="2009-09-29 14:37:48 +0100" MODIFIED_BY="Jill V Hampson" NAME="Viero 2004" TYPE="JOURNAL_ARTICLE">
<AU>Viero S, Chaddha V, Alkazaleh F, Simchen M, Malik A, Kelly E, et al</AU>
<TI>Prognostic value of placental ultrasound in pregnancies complicated by absent end-diastolic flow velocity in the umbilical arteries</TI>
<SO>Placenta</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>8-9</NO>
<PG>735-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walker-2003" MODIFIED="2009-09-29 14:38:50 +0100" MODIFIED_BY="Jill V Hampson" NAME="Walker 2003" TYPE="COCHRANE_REVIEW">
<AU>Walker MC, Ferguson SE, Allen VM</AU>
<TI>Heparin for pregnant women with acquired or inherited thrombophilias</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2009-09-29 14:38:50 +0100" MODIFIED_BY="Jill V Hampson">
<IDENTIFIER MODIFIED="2009-09-29 14:38:50 +0100" MODIFIED_BY="Jill V Hampson" TYPE="DOI" VALUE="10.1002/14651858.CD003580"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Walker-2012" MODIFIED="2013-05-22 12:12:40 +0100" MODIFIED_BY="[Empty name]" NAME="Walker 2012" TYPE="JOURNAL_ARTICLE">
<AU>Walker MG, Fitzgerald B, Keating S, Ray JG, Windrim R, Kingdom JC</AU>
<TI>Sex-specific basis of severe placental dysfunction leading to extreme preterm delivery</TI>
<SO>Placenta</SO>
<YR>2012</YR>
<VL>33</VL>
<NO>7</NO>
<PG>568-71</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-07-12 15:34:10 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Dodd-2010" MODIFIED="2013-07-12 15:34:10 +0100" MODIFIED_BY="[Empty name]" NAME="Dodd 2010" TYPE="COCHRANE_REVIEW">
<AU>Dodd JM, McLeod A, Windrim RC, Kingdom J</AU>
<TI>Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2013-06-12 15:43:02 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-12 15:43:02 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006780.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2009-09-29 12:23:35 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-07-12 15:53:11 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-07-12 15:53:11 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-07-12 15:40:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gris-2010">
<CHAR_METHODS MODIFIED="2012-08-29 04:04:10 +0100" MODIFIED_BY="[Empty name]">
<P>Trial conducted in France between January 2000 and 2009.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-29 04:04:33 +0100" MODIFIED_BY="[Empty name]">
<P>160 women with placental abruption in a previous pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-29 04:04:51 +0100" MODIFIED_BY="[Empty name]">
<P>Women were randomised to (1) subcutaneous enoxaparin or (2) no treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-18 12:26:59 +0100" MODIFIED_BY="[Empty name]">
<P>Perinatal mortality; pre-eclampsia; preterm birth less than 37 and 34 weeks; NICU admission.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-12 15:40:39 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation: computer-generated.<BR/>Allocation concealment: sealed opaque envelopes.<BR/>Blinding of participants, caregivers: no; outcome assessors: not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-12 15:45:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gris-2011">
<CHAR_METHODS MODIFIED="2012-08-29 03:59:26 +0100" MODIFIED_BY="[Empty name]">
<P>Trial conducted in France between January 2000 and 2010.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-29 03:59:55 +0100" MODIFIED_BY="[Empty name]">
<P>224 women with severe pre-eclampsia in a previous pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-29 04:00:30 +0100" MODIFIED_BY="[Empty name]">
<P>Women were randomised to (1) subcutaneous enoxaparin and aspirin or (2) aspirin alone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-18 12:27:14 +0100" MODIFIED_BY="[Empty name]">
<P>Perinatal mortality; pre-eclampsia; preterm birth less than 37 and 34 weeks; NICU admission.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-12 15:45:25 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation: computer-generated.<BR/>Allocation concealment: sealed opaque envelopes.<BR/>Blinding of participants, caregivers: no; outcome assessors: not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-12 15:45:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kincaid_x002d_Smith-1995">
<CHAR_METHODS MODIFIED="2009-10-02 15:40:13 +0100" MODIFIED_BY="[Empty name]">
<P>Trial conducted in Australia.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-09 11:36:31 +0100" MODIFIED_BY="[Empty name]">
<P>21 women with primary glomerulonephritis or reflux nephropathy who were considered on clinical grounds to be at high risk of developing pre-eclampsia; randomised from 14 weeks' gestation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-02 15:40:14 +0100" MODIFIED_BY="[Empty name]">
<P>Women were randomised to (1) subcutaneous heparin and dipyridamole or (2) no treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-12 15:45:51 +0100" MODIFIED_BY="[Empty name]">
<P>Perinatal mortality; pre-eclampsia; length of antenatal stay; preterm birth less than 37 weeks; infant birthweight &lt; 2500 g; infant birthweight less than 10th centile for gestational age.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-10-02 15:40:20 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation: stated "randomized by the envelope method".<BR/>Allocation concealment: "envelope method".<BR/>Blinding of participants, caregivers and outcome assessors: no.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-12 15:46:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kingdom-2011">
<CHAR_METHODS MODIFIED="2012-08-29 03:48:50 +0100" MODIFIED_BY="[Empty name]">
<P>Trial conducted in Toronto, Canada between March 2007 and May 2010.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-18 12:27:43 +0100" MODIFIED_BY="[Empty name]">
<P>32 women with a singleton pregnancy and negative thrombophilia screen, who had 2 or more of the following: abnormal first or second trimester maternal serum screening (in the absence of a chromosomal fetal anomaly); abnormal placental morphology detected on ultrasound; abnormal maternal uterine artery Doppler waveform prior to 24 weeks' gestation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-24 16:24:23 +0100" MODIFIED_BY="[Empty name]">
<P>Women were randomised to (1) subcutaneous heparin 7500 IU twice daily and medical surveillance or (2) medical surveillance only.</P>
<P>8 of 16 women in the control group received low-dose aspirin alone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-12 15:46:05 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes related to feasibility of recruitment and maternal emotional wellbeing.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-12 15:46:32 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation: computer-generated.<BR/>Allocation concealment: central telephone randomisation.<BR/>Blinding of participants, caregivers and outcome assessors: no.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-18 12:28:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martinelli-2012">
<CHAR_METHODS MODIFIED="2012-08-29 03:41:51 +0100" MODIFIED_BY="[Empty name]">
<P>Trial conducted in 8 centres in Italy, between April 2007 and April 2010.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-14 12:28:02 +0100" MODIFIED_BY="[Empty name]">
<P>135 women with a history of pre-eclampsia, eclampsia, HELLP syndrome, previous fetal loss or fetal growth restriction, with gestational age less than 12 weeks' gestation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-29 03:43:36 +0100" MODIFIED_BY="[Empty name]">
<P>Women were randomised to (1) low molecular weight heparin and medical surveillance or (2) medical surveillance only.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-29 03:44:26 +0100" MODIFIED_BY="[Empty name]">
<P>Pre-eclampsia; eclampsia, HELLP syndrome, placental abruption, fetal growth restriction, or fetal death.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-18 12:28:25 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation: computer-generated random number sequence.<BR/>Allocation concealment: central telephone randomisation.<BR/>Blinding of participants and caregivers: no; outcome assessors: not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-04-20 13:48:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mello-2005">
<CHAR_METHODS MODIFIED="2009-10-02 15:40:29 +0100" MODIFIED_BY="[Empty name]">
<P>Trial conducted in Italy, between January 2001 and December 2002.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-02 15:40:30 +0100" MODIFIED_BY="[Empty name]">
<P>80 women with a history of pre-eclampsia who were negative on thrombophilia testing; treatment was started as soon as pregnancy was confirmed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-09 11:37:06 +0100" MODIFIED_BY="[Empty name]">
<P>Women were randomised to (1) low molecular weight heparin or (2) no treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-09 11:37:08 +0100" MODIFIED_BY="[Empty name]">
<P>Pre-eclampsia; infant birthweight less than 10th centile for gestational age.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-20 13:48:56 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation: computer-generated random number sequence.<BR/>Allocation concealment: not stated.<BR/>Blinding of participants, caregivers, and outcome assessors: no.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-04-20 13:48:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nieder-1995">
<CHAR_METHODS MODIFIED="2009-10-02 15:40:45 +0100" MODIFIED_BY="[Empty name]">
<P>Trial conducted in Germany.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-09 11:37:25 +0100" MODIFIED_BY="[Empty name]">
<P>160 women at increased risk of developing pre-eclampsia, between 22 and 38 weeks' gestation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-02 15:40:47 +0100" MODIFIED_BY="[Empty name]">
<P>Women were randomised to (1) triazolopyrimidine or (2) placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-02 15:40:49 +0100" MODIFIED_BY="[Empty name]">
<P>Rate of pre-eclampsia; rate of preterm birth.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-20 13:48:56 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation: not stated.<BR/>Allocation concealment: not stated.<BR/>Blinding of participants, caregivers, and outcome assessors: not stated.<BR/>Study stated to be "randomised, double blind, placebo control".</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-09 11:38:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rey-2009">
<CHAR_METHODS MODIFIED="2009-10-02 15:41:53 +0100" MODIFIED_BY="[Empty name]">
<P>Trial conducted in Canada between August 2000 and June 2007.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-09 11:37:45 +0100" MODIFIED_BY="[Empty name]">
<P>116 women with past history of severe pre-eclampsia, fetal growth restriction (infant birthweight less than 5th centile), unexplained fetal death or abruption, in the absence of a known thrombophilia; women randomised from 17 weeks' gestation.</P>
<P>Original sample size 276 women; trial stopped after an interim analysis due to slow recruitment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-09 11:37:51 +0100" MODIFIED_BY="[Empty name]">
<P>Women were randomised to (1) low molecular weight heparin or (2) no treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-09 11:37:57 +0100" MODIFIED_BY="[Empty name]">
<P>Primary composite of severe pre-eclampsia, infant birthweight less than 5th centile, abruption requiring birth less than 34 weeks' gestation, or fetal death after 20 weeks.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-10-09 11:38:06 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation: computer-generated random number table.<BR/>Allocation concealment: sealed opaque envelopes.<BR/>Blinding of participants and caregivers: no.<BR/>Blinding of outcome assessors: yes.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-18 12:38:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yu-2004a">
<CHAR_METHODS MODIFIED="2009-10-02 15:42:13 +0100" MODIFIED_BY="[Empty name]">
<P>Trial conducted in China.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-02 15:42:14 +0100" MODIFIED_BY="[Empty name]">
<P>107 women with established fetal growth restriction.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-09 11:38:25 +0100" MODIFIED_BY="[Empty name]">
<P>Women were randomised to (1) standard heparin infusion, (2) low molecular weight heparin, or (3) dextran infusion.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-18 12:38:04 +0100" MODIFIED_BY="[Empty name]">
<P>Major neurodevelopmental handicap at child follow-up; antepartum haemorrhage, thrombocytopaenia, preterm birth less than 37 weeks' gestation, infant birthweight less than 10th centile.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-20 13:48:56 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation: stated "women were randomised into three groups".<BR/>Allocation concealment: not stated.<BR/>Blinding of participants, caregivers, and outcome assessors: not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-18 12:29:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yu-2010">
<CHAR_METHODS MODIFIED="2012-08-29 03:54:25 +0100" MODIFIED_BY="[Empty name]">
<P>Trial conducted in China.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-29 03:55:39 +0100" MODIFIED_BY="[Empty name]">
<P>104 women, 73 with established fetal growth restriction, and 31 with established pre-eclampsia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-29 03:56:19 +0100" MODIFIED_BY="[Empty name]">
<P>Women were randomised to (1) standard heparin infusion, or (2) the control group (no details provided as to what this comprised).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-18 12:29:39 +0100" MODIFIED_BY="[Empty name]">
<P>Ultrasound and haematological measures; no prespecified review outcomes were reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-29 03:57:04 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation: not stated.<BR/>Allocation concealment: not stated.<BR/>Blinding of participants, caregivers, and outcome assessors: not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>HELLP: haemolysis, elevated liver enzymes, low platelet count<BR/>IU: international units<BR/>NICU: neonatal intensive care unit</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-05-22 12:12:05 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-05-22 12:11:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Airoldi-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-22 12:11:58 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-22 12:12:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eid-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-22 12:12:05 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-06-25 14:47:51 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2010-04-20 13:48:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bonnar-1980">
<CHAR_METHODS MODIFIED="2009-10-02 15:42:37 +0100" MODIFIED_BY="[Empty name]">
<P>Study conducted in Ireland.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-02 15:42:37 +0100" MODIFIED_BY="[Empty name]">
<P>40 women at high risk of fetal growth restriction.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-02 15:42:40 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment with heparin and dipyridamole or no treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-02 15:42:40 +0100" MODIFIED_BY="[Empty name]">
<P>Infant growth restriction.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-20 13:48:56 +0100" MODIFIED_BY="[Empty name]">
<P>There is insufficient information presented in the abstract to evaluate study methodology; no data are presented.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-06-24 16:24:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferrier-2000">
<CHAR_METHODS MODIFIED="2009-10-02 15:42:50 +0100" MODIFIED_BY="[Empty name]">
<P>Trial conducted in Switzerland.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-02 15:42:50 +0100" MODIFIED_BY="[Empty name]">
<P>24 women with a history of pre-eclampsia, renal disease, or hypertension.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-24 16:24:26 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment with heparin and low-dose aspirin or low-dose aspirin alone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-02 15:42:52 +0100" MODIFIED_BY="[Empty name]">
<P>Hypertension, fetal loss, uric acid renal clearance.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-10-02 15:42:52 +0100" MODIFIED_BY="[Empty name]">
<P>There is insufficient information presented in the abstract to evaluate study methodology.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-06-25 14:47:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yu-2004b">
<CHAR_METHODS MODIFIED="2013-05-01 05:54:03 +0100" MODIFIED_BY="[Empty name]">
<P>Trial conducted in China.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-01 05:55:32 +0100" MODIFIED_BY="[Empty name]">
<P>Women with established fetal growth restriction. </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-01 05:54:30 +0100" MODIFIED_BY="[Empty name]">
<P>Women were randomised to (1) standard heparin infusion, (2) low molecular weight heparin, or (3) dextran infusion.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-01 05:55:28 +0100" MODIFIED_BY="[Empty name]">
<P>Doppler ultrasound parameters reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-25 14:47:51 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation: stated "women were randomised into three groups".<BR/>Allocation concealment: not stated.<BR/>Blinding of participants, caregivers, and outcome assessors: not stated.</P>
<P>This could be an additional report of <LINK REF="STD-Yu-2004a" TYPE="STUDY">Yu 2004a</LINK>. Awaiting further clarification from authors.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-05-01 05:52:17 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-07-12 15:46:39 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-07-12 15:46:39 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-12 15:40:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gris-2010">
<DESCRIPTION>
<P>Computer-generated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-12 15:45:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gris-2011">
<DESCRIPTION>
<P>Computer-generated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-09 11:36:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kincaid_x002d_Smith-1995">
<DESCRIPTION>
<P>Stated "randomized by the envelope method".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-12 15:46:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kingdom-2011">
<DESCRIPTION>
<P>Computer-generated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-18 12:28:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martinelli-2012">
<DESCRIPTION>
<P>Computer-generated randomisation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-09 11:37:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mello-2005">
<DESCRIPTION>
<P>Computer-generated random number sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-02 15:41:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nieder-1995">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-09 11:38:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rey-2009">
<DESCRIPTION>
<P>Computer-generated random number table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-09 11:38:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yu-2004a">
<DESCRIPTION>
<P>Method of randomisation: stated "women were randomised into three groups".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-18 12:29:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yu-2010">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-06-18 12:29:42 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-18 12:27:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gris-2010">
<DESCRIPTION>
<P>Sealed opaque envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-18 12:27:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gris-2011">
<DESCRIPTION>
<P>Sealed opaque envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-09 11:36:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kincaid_x002d_Smith-1995">
<DESCRIPTION>
<P>"Envelope method."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-18 12:28:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kingdom-2011">
<DESCRIPTION>
<P>Central telephone randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-18 12:28:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martinelli-2012">
<DESCRIPTION>
<P>Central telephone randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-02 15:40:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mello-2005">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-02 15:41:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nieder-1995">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-02 15:42:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rey-2009">
<DESCRIPTION>
<P>Sealed opaque envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-02 15:42:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yu-2004a">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-18 12:29:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yu-2010">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-06-12 15:36:40 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-06-18 12:29:43 +0100" MODIFIED_BY="Denise Atherton" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-18 12:27:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gris-2010">
<DESCRIPTION>
<P>Blinding of participants, caregivers: no.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-18 12:27:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gris-2011">
<DESCRIPTION>
<P>Blinding of participants, caregivers: no.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-29 03:39:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kincaid_x002d_Smith-1995">
<DESCRIPTION>
<P>No blinding of participants, caregivers, or outcome assessors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-29 03:52:55 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kingdom-2011">
<DESCRIPTION>
<P>Blinding of participants, caregivers and outcome assessors: no.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-18 12:28:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Martinelli-2012">
<DESCRIPTION>
<P>Blinding of participants and caregivers: no.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-29 03:39:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mello-2005">
<DESCRIPTION>
<P>No blinding of participants, caregivers, or outcome assessors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-29 03:39:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nieder-1995">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-29 03:40:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rey-2009">
<DESCRIPTION>
<P>No blinding of participants or caregivers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-29 03:40:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yu-2004a">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-18 12:29:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yu-2010">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-06-18 12:29:43 +0100" MODIFIED_BY="Denise Atherton" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-18 12:27:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gris-2010">
<DESCRIPTION>
<P>Blinding of outcome assessors: not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-18 12:27:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gris-2011">
<DESCRIPTION>
<P>Blinding of outcome assessors: not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-29 03:39:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kincaid_x002d_Smith-1995">
<DESCRIPTION>
<P>No blinding of participants, caregivers, or outcome assessors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-29 03:53:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kingdom-2011">
<DESCRIPTION>
<P>Blinding of participants, caregivers and outcome assessors: no.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-18 12:28:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martinelli-2012">
<DESCRIPTION>
<P>Blinding of outcome assessors: not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-29 03:39:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mello-2005">
<DESCRIPTION>
<P>No blinding of participants, caregivers, or outcome assessors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-29 03:39:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nieder-1995">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-18 12:29:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rey-2009">
<DESCRIPTION>
<P>Blinding of outcome assessors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-29 03:40:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yu-2004a">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-18 12:29:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yu-2010">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-06-18 12:29:44 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-18 12:27:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gris-2010">
<DESCRIPTION>
<P>Appears complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-18 12:27:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gris-2011">
<DESCRIPTION>
<P>Appears complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-18 12:27:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kincaid_x002d_Smith-1995">
<DESCRIPTION>
<P>Appears complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-18 12:28:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kingdom-2011">
<DESCRIPTION>
<P>Outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-18 12:28:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martinelli-2012">
<DESCRIPTION>
<P>135 women randomised; 128 women analysed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-18 12:28:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mello-2005">
<DESCRIPTION>
<P>Appears complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-04-20 13:48:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nieder-1995">
<DESCRIPTION>
<P>Unable to assess.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-18 12:29:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rey-2009">
<DESCRIPTION>
<P>Appears complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-04-20 13:48:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yu-2004a">
<DESCRIPTION>
<P>Unable to assess.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-18 12:29:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yu-2010">
<DESCRIPTION>
<P>Unable to assess.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-06-18 12:29:45 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-18 12:27:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gris-2010">
<DESCRIPTION>
<P>Appears complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-18 12:27:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gris-2011">
<DESCRIPTION>
<P>Appears complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-18 12:27:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kincaid_x002d_Smith-1995">
<DESCRIPTION>
<P>Appears complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-18 12:28:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kingdom-2011">
<DESCRIPTION>
<P>Expected outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-18 12:28:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martinelli-2012">
<DESCRIPTION>
<P>Appears complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-18 12:28:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mello-2005">
<DESCRIPTION>
<P>Appears complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-20 13:48:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nieder-1995">
<DESCRIPTION>
<P>Unable to assess.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-18 12:29:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rey-2009">
<DESCRIPTION>
<P>Appears complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-20 13:48:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yu-2004a">
<DESCRIPTION>
<P>Unable to assess.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-18 12:29:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yu-2010">
<DESCRIPTION>
<P>Unable to assess.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-06-18 12:29:45 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-18 12:27:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gris-2010">
<DESCRIPTION>
<P>No other potential bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-18 12:27:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gris-2011">
<DESCRIPTION>
<P>No other potential bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-18 12:27:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kincaid_x002d_Smith-1995">
<DESCRIPTION>
<P>No other potential bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-18 12:28:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kingdom-2011">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-18 12:28:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Martinelli-2012">
<DESCRIPTION>
<P>Trial stopped after 135 women randomised due to futility (estimated sample size 266 women).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-18 12:28:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mello-2005">
<DESCRIPTION>
<P>No other potential bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-18 12:29:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nieder-1995">
<DESCRIPTION>
<P>No other potential bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-02 15:42:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rey-2009">
<DESCRIPTION>
<P>Trial stopped early after interim analysis due to slow recruitment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-01 04:21:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yu-2004a">
<DESCRIPTION>
<P>No other potential bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-18 12:29:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yu-2010">
<DESCRIPTION>
<P>No other potential bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-06-18 12:38:25 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-06-18 12:38:18 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Heparin (alone or with other medication) versus no treatment</NAME>
<DICH_OUTCOME CHI2="1.3715221572687069" CI_END="0.784086145970667" CI_START="0.20172807596436698" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.397708674304419" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.10563621963138632" LOG_CI_START="-0.6952336536570977" LOG_EFFECT_SIZE="-0.40043493664424207" METHOD="MH" MODIFIED="2013-05-01 05:44:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8491292390250453" P_Q="1.0" P_Z="0.0077612249639816356" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="340" TOTAL_2="313" WEIGHT="99.99999999999999" Z="2.6622844967811283">
<NAME>Perinatal mortality</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5987529735035928" CI_START="0.11488545912458459" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.2037813652271334" LOG_CI_START="-0.9397349358163223" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2012-08-29 04:12:02 +0100" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.6717071357299074" STUDY_ID="STD-Gris-2010" TOTAL_1="80" TOTAL_2="80" VAR="0.45119047619047614" WEIGHT="25.20458265139116"/>
<DICH_DATA CI_END="1.1078228959660772" CI_START="0.11936150213194976" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.04447033669888445" LOG_CI_START="-0.9231357243594097" LOG_EFFECT_SIZE="-0.43933269383026263" MODIFIED="2012-08-29 04:19:24 +0100" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.568376589992892" STUDY_ID="STD-Gris-2011" TOTAL_1="112" TOTAL_2="112" VAR="0.32305194805194803" WEIGHT="39.607201309328964"/>
<DICH_DATA CI_END="4.441405958154779" CI_START="0.01296886628754162" EFFECT_SIZE="0.24" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6475204708383532" LOG_CI_START="-1.8870979874151412" LOG_EFFECT_SIZE="-0.619788758288394" MODIFIED="2009-09-17 06:57:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="1.4888474289418194" STUDY_ID="STD-Kincaid_x002d_Smith-1995" TOTAL_1="9" TOTAL_2="11" VAR="2.2166666666666663" WEIGHT="8.183306055646481"/>
<DICH_DATA CI_END="2.560009619986433" CI_START="0.007971908818613843" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.40824159730371434" LOG_CI_START="-2.098437677332228" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2012-08-29 04:26:03 +0100" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="1.47243581418368" STUDY_ID="STD-Kingdom-2011" TOTAL_1="16" TOTAL_2="16" VAR="2.1680672268907566" WEIGHT="12.60229132569558"/>
<DICH_DATA CI_END="3.1958603301025805" CI_START="0.1760089434139773" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.504587790920053" LOG_CI_START="-0.754465264136653" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2009-09-17 06:57:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.7395739969534467" STUDY_ID="STD-Rey-2009" TOTAL_1="55" TOTAL_2="55" VAR="0.5469696969696969" WEIGHT="14.402618657937806"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 06:57:56 +0100" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.0" STUDY_ID="STD-Yu-2004a" TOTAL_1="68" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1898684158484111" CI_END="0.7294182598291932" CI_START="0.2879958674103334" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4583333333333333" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.13702336901264195" LOG_CI_START="-0.54061374409412" LOG_EFFECT_SIZE="-0.338818556553381" METHOD="MH" MODIFIED="2013-05-01 05:44:13 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9094328253458246" P_Q="1.0" P_Z="9.989488049088502E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="247" TOTAL_2="247" WEIGHT="100.0" Z="3.290822621844782">
<NAME>Preterm birth less than 34 weeks' gestation</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.001674334280597" CI_START="0.07993308264978286" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.30139342063094" LOG_CI_START="-1.097273437975015" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2012-08-29 04:12:23 +0100" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="0.8215838362577492" STUDY_ID="STD-Gris-2010" TOTAL_1="80" TOTAL_2="80" VAR="0.675" WEIGHT="10.416666666666668"/>
<DICH_DATA CI_END="0.7742531920996416" CI_START="0.24721402759856778" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="32" LOG_CI_END="-0.11111699545338126" LOG_CI_START="-0.6069268898299547" LOG_EFFECT_SIZE="-0.3590219426416679" MODIFIED="2012-08-29 04:19:52 +0100" MODIFIED_BY="[Empty name]" ORDER="36" O_E="0.0" SE="0.2912411862553588" STUDY_ID="STD-Gris-2011" TOTAL_1="112" TOTAL_2="112" VAR="0.08482142857142858" WEIGHT="66.66666666666667"/>
<DICH_DATA CI_END="1.3712158574055253" CI_START="0.2169758025698178" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.1371058270002838" LOG_CI_START="-0.6635886965494467" LOG_EFFECT_SIZE="-0.26324143477458145" MODIFIED="2009-09-17 06:58:23 +0100" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.4703319266349258" STUDY_ID="STD-Rey-2009" TOTAL_1="55" TOTAL_2="55" VAR="0.2212121212121212" WEIGHT="22.916666666666668"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-18 12:38:18 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="68" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>Major neurodevelopmental delay at child follow-up</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 06:58:58 +0100" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="0.0" STUDY_ID="STD-Yu-2004a" TOTAL_1="68" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.241428573422267" CI_END="1.0271906327677596" CI_START="0.2181312836375217" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4733523119897795" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="64" I2="57.86939513078512" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.01165105029270845" LOG_CI_START="-0.6612820449355042" LOG_EFFECT_SIZE="-0.3248154973213979" METHOD="MH" MODIFIED="2013-05-01 05:44:13 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.027052559196818815" P_Q="1.0" P_Z="0.05847832283004026" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.5808657057654413" TOTALS="YES" TOTAL_1="380" TOTAL_2="381" WEIGHT="99.99999999999999" Z="1.8920950117767839">
<NAME>Pre-eclampsia</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7959666479918488" CI_START="0.13959267186814206" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="18" LOG_CI_END="-0.0991051293685591" LOG_CI_START="-0.8551373800707659" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2012-08-29 04:12:51 +0100" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.4440970864824742" STUDY_ID="STD-Gris-2010" TOTAL_1="80" TOTAL_2="80" VAR="0.1972222222222222" WEIGHT="20.081229617205803"/>
<DICH_DATA CI_END="0.8621193222157655" CI_START="0.14448982970047275" EFFECT_SIZE="0.35294117647058826" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.0644326211897294" LOG_CI_START="-0.840162720799531" LOG_EFFECT_SIZE="-0.45229767099463025" MODIFIED="2012-08-29 04:20:58 +0100" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="0.4556677004367201" STUDY_ID="STD-Gris-2011" TOTAL_1="112" TOTAL_2="112" VAR="0.2076330532212885" WEIGHT="19.81608996363573"/>
<DICH_DATA CI_END="1.7422611945037307" CI_START="0.006830678708694336" EFFECT_SIZE="0.10909090909090909" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.24111326366148864" LOG_CI_START="-2.165536141882689" LOG_EFFECT_SIZE="-0.9622114391106003" MODIFIED="2009-09-17 06:59:34 +0100" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="1.4136777739233395" STUDY_ID="STD-Kincaid_x002d_Smith-1995" TOTAL_1="9" TOTAL_2="11" VAR="1.9984848484848483" WEIGHT="6.057711821508377"/>
<DICH_DATA CI_END="12.693711628894878" CI_START="0.7090124829614981" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1035886279465654" LOG_CI_START="-0.14934611850724053" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-08-29 04:26:44 +0100" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.7359800721939872" STUDY_ID="STD-Kingdom-2011" TOTAL_1="16" TOTAL_2="16" VAR="0.5416666666666666" WEIGHT="13.919386850681832"/>
<DICH_DATA CI_END="6.798253871289257" CI_START="0.42088974141748875" EFFECT_SIZE="1.691542288557214" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8323973786703057" LOG_CI_START="-0.3758316594267732" LOG_EFFECT_SIZE="0.22828285962176628" MODIFIED="2012-08-29 04:28:34 +0100" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="0.7097197178084204" STUDY_ID="STD-Martinelli-2012" TOTAL_1="67" TOTAL_2="68" VAR="0.5037020778460638" WEIGHT="14.406625920849834"/>
<DICH_DATA CI_END="0.8604252438004716" CI_START="0.07821778191983392" EFFECT_SIZE="0.25942350332594233" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.06528685644075638" LOG_CI_START="-1.1066945038228415" LOG_EFFECT_SIZE="-0.5859906801317989" MODIFIED="2009-09-17 06:59:50 +0100" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="0.6117280071232308" STUDY_ID="STD-Mello-2005" TOTAL_1="41" TOTAL_2="39" VAR="0.3742111546989595" WEIGHT="16.359900434294484"/>
<DICH_DATA CI_END="0.9661275168577538" CI_START="0.016172813347475043" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.014965548312474325" LOG_CI_START="-1.7912144256714129" LOG_EFFECT_SIZE="-0.9030899869919435" MODIFIED="2012-11-27 02:11:39 +0000" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="1.0433773831343882" STUDY_ID="STD-Rey-2009" TOTAL_1="55" TOTAL_2="55" VAR="1.0886363636363638" WEIGHT="9.359055391823924"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-05-01 05:44:13 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="68" WEIGHT="0.0" Z="0.0">
<NAME>Eclampsia</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-08-29 04:28:53 +0100" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="0.0" STUDY_ID="STD-Martinelli-2012" TOTAL_1="67" TOTAL_2="68" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.07583927757908879" CI_END="1.398450464108432" CI_START="0.10107902867322127" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3759707629054363" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.14564708740731072" LOG_CI_START="-0.9953389401186343" LOG_EFFECT_SIZE="-0.4248459263556618" METHOD="MH" MODIFIED="2013-06-18 12:30:22 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.9945699910655746" P_Q="1.0" P_Z="0.14440432370092418" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="275" TOTAL_2="276" WEIGHT="100.0" Z="1.4595844200497345">
<NAME>Placental abruption</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.136920379290268" CI_START="0.035420443516723916" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4965034956586265" LOG_CI_START="-1.4507460050979515" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2012-08-29 04:14:01 +0100" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="1.1438239957848992" STUDY_ID="STD-Gris-2010" TOTAL_1="80" TOTAL_2="80" VAR="1.3083333333333333" WEIGHT="37.5513933302878"/>
<DICH_DATA CI_END="5.435640983700315" CI_START="0.04599273586126587" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7352507644793567" LOG_CI_START="-1.3373107558073192" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2012-08-29 04:21:23 +0100" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="1.2174328963613794" STUDY_ID="STD-Gris-2011" TOTAL_1="112" TOTAL_2="112" VAR="1.4821428571428572" WEIGHT="25.034262220191867"/>
<DICH_DATA CI_END="7.618637080220918" CI_START="0.014584119172649873" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8818772861059678" LOG_CI_START="-1.8361197955452926" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2012-08-29 04:27:00 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="1.5965649400644928" STUDY_ID="STD-Kingdom-2011" TOTAL_1="16" TOTAL_2="16" VAR="2.5490196078431375" WEIGHT="18.7756966651439"/>
<DICH_DATA CI_END="8.1581999958811" CI_START="0.01402308281785331" EFFECT_SIZE="0.3382352941176471" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9115943477134757" LOG_CI_START="-1.8531565010907625" LOG_EFFECT_SIZE="-0.47078107668864344" MODIFIED="2012-08-29 04:29:12 +0100" MODIFIED_BY="[Empty name]" ORDER="52" O_E="0.0" SE="1.6240283343250317" STUDY_ID="STD-Martinelli-2012" TOTAL_1="67" TOTAL_2="68" VAR="2.637468030690537" WEIGHT="18.638647784376424"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-05-01 05:44:13 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="68" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>Antepartum haemorrhage (after 20 weeks requiring hospitalisation)</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 07:00:48 +0100" MODIFIED_BY="[Empty name]" ORDER="9" O_E="0.0" SE="0.0" STUDY_ID="STD-Yu-2004a" TOTAL_1="68" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-2.8586531486461997" CI_START="-15.1413468513538" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2013-05-01 05:44:13 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.004075200091439677" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="11" UNITS="" WEIGHT="100.0" Z="2.8722813232690143">
<NAME>Mean length of antenatal hospital stay</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.8586531486461997" CI_START="-15.1413468513538" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="18.0" MEAN_2="27.0" MODIFIED="2009-09-17 07:01:19 +0100" MODIFIED_BY="[Empty name]" ORDER="10" SD_1="6.0" SD_2="8.0" SE="3.1333978072025612" STUDY_ID="STD-Kincaid_x002d_Smith-1995" TOTAL_1="9" TOTAL_2="11" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-05-01 05:44:13 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="135" TOTAL_2="107" WEIGHT="0.0" Z="0.0">
<NAME>Thrombocytopaenia</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-08-29 04:29:39 +0100" MODIFIED_BY="[Empty name]" ORDER="53" O_E="0.0" SE="0.0" STUDY_ID="STD-Martinelli-2012" TOTAL_1="67" TOTAL_2="68" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 07:02:19 +0100" MODIFIED_BY="[Empty name]" ORDER="11" O_E="0.0" SE="0.0" STUDY_ID="STD-Yu-2004a" TOTAL_1="68" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.7583968074161893" CI_END="0.8990202571186663" CI_START="0.5769351956806092" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7201919382786712" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="118" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-0.046230522442811166" LOG_CI_START="-0.23887296628777605" LOG_EFFECT_SIZE="-0.14255174436529358" METHOD="MH" MODIFIED="2013-05-01 05:44:13 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.4396896042438473" P_Q="1.0" P_Z="0.00372363252855331" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="324" TOTAL_2="297" WEIGHT="100.00000000000001" Z="2.900672139668131">
<NAME>Preterm birth less than 37 weeks' gestation</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2245496594229324" CI_START="0.6206578007183461" EFFECT_SIZE="0.8717948717948718" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="39" LOG_CI_END="0.0879764018544008" LOG_CI_START="-0.20714778182288898" LOG_EFFECT_SIZE="-0.05958568998424408" MODIFIED="2012-08-29 04:14:48 +0100" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="0.17335740638031014" STUDY_ID="STD-Gris-2010" TOTAL_1="80" TOTAL_2="80" VAR="0.030052790346907995" WEIGHT="32.718890396029515"/>
<DICH_DATA CI_END="0.9753909140432241" CI_START="0.4556577655640834" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="45" LOG_CI_END="-0.010821294263490126" LOG_CI_START="-0.3413612238478724" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2012-08-29 04:21:49 +0100" MODIFIED_BY="[Empty name]" ORDER="39" O_E="0.0" SE="0.19416079083690585" STUDY_ID="STD-Gris-2011" TOTAL_1="112" TOTAL_2="112" VAR="0.0376984126984127" WEIGHT="37.75256584157252"/>
<DICH_DATA CI_END="1.2830456244428319" CI_START="0.09504344350886343" EFFECT_SIZE="0.3492063492063492" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.10824209993803209" LOG_CI_START="-1.022077837200783" LOG_EFFECT_SIZE="-0.4569178686313755" MODIFIED="2009-09-17 07:02:50 +0100" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="0.6639555262492667" STUDY_ID="STD-Kincaid_x002d_Smith-1995" TOTAL_1="9" TOTAL_2="11" VAR="0.4408369408369407" WEIGHT="5.285359217820152"/>
<DICH_DATA CI_END="1.3739169594334522" CI_START="0.4658214571162367" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.13796048443410422" LOG_CI_START="-0.331780510450217" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2009-09-17 07:03:02 +0100" MODIFIED_BY="[Empty name]" ORDER="13" O_E="0.0" SE="0.27592818565047617" STUDY_ID="STD-Rey-2009" TOTAL_1="55" TOTAL_2="55" VAR="0.07613636363636364" WEIGHT="16.778918151810007"/>
<DICH_DATA CI_END="1.2039166681668123" CI_START="0.1393987533952946" EFFECT_SIZE="0.4096638655462185" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.08059642728077814" LOG_CI_START="-0.8557411099967285" LOG_EFFECT_SIZE="-0.38757234135797514" MODIFIED="2009-09-17 07:03:16 +0100" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="0.5500093043423684" STUDY_ID="STD-Yu-2004a" TOTAL_1="68" TOTAL_2="39" VAR="0.302510234863176" WEIGHT="7.464266392767817"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8167566715694172" CI_START="0.3684706367556761" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" I2="0.0" I2_Q="100.0" ID="CMP-001.11" LOG_CI_END="0.2592967637024869" LOG_CI_START="-0.43359711514028715" LOG_EFFECT_SIZE="-0.08715017571890014" METHOD="MH" MODIFIED="2013-05-01 05:44:13 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.621986352048255" Q="4.650416207178935E-33" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="55" TOTAL_2="55" WEIGHT="100.00000000000001" Z="0.4930371327299328">
<NAME>Infant birthweight less than 2500 grams</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8167566715694172" CI_START="0.3684706367556761" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.2592967637024869" LOG_CI_START="-0.43359711514028715" LOG_EFFECT_SIZE="-0.08715017571890014" MODIFIED="2009-09-17 07:03:47 +0100" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.4070092943122622" STUDY_ID="STD-Rey-2009" TOTAL_1="55" TOTAL_2="55" VAR="0.16565656565656564" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.296602462841412" CI_END="0.6100927398747833" CI_START="0.2743072318056742" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.40908782751359285" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="65" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="-0.21460414309658163" LOG_CI_START="-0.5617627425526082" LOG_EFFECT_SIZE="-0.3881834428245948" METHOD="MH" MODIFIED="2013-06-14 12:29:02 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.636606552492538" P_Q="1.0" P_Z="1.1697099473611799E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="368" TOTAL_2="342" WEIGHT="100.0" Z="4.383158409574932">
<NAME>Infant birthweight less than 10th centile for gestational age</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1990286243247332" CI_START="0.09266760514052486" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.07882955110376266" LOG_CI_START="-1.0330720605430876" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2012-08-29 04:24:03 +0100" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.6531365106831049" STUDY_ID="STD-Gris-2011" TOTAL_1="112" TOTAL_2="112" VAR="0.4265873015873015" WEIGHT="13.55946168921449"/>
<DICH_DATA CI_END="7.03924511695163" CI_START="0.21221411325718045" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8475260882443147" LOG_CI_START="-0.6732257368065142" LOG_EFFECT_SIZE="0.0871501757189002" MODIFIED="2009-09-17 07:04:22 +0100" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="0.8932971498777984" STUDY_ID="STD-Kincaid_x002d_Smith-1995" TOTAL_1="9" TOTAL_2="11" VAR="0.7979797979797979" WEIGHT="2.7118923378428983"/>
<DICH_DATA CI_END="0.9998047506785239" CI_START="0.25004882186280464" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="-8.480398214183643E-5" LOG_CI_START="-0.6019751873458205" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2012-08-29 04:25:31 +0100" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="0.3535533905932738" STUDY_ID="STD-Kingdom-2011" TOTAL_1="16" TOTAL_2="16" VAR="0.125" WEIGHT="18.079282252285985"/>
<DICH_DATA CI_END="2.171173489734632" CI_START="0.2420569858720837" EFFECT_SIZE="0.7249466950959488" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.33669452756499313" LOG_CI_START="-0.6160823789106494" LOG_EFFECT_SIZE="-0.13969392567282818" MODIFIED="2012-08-29 04:30:08 +0100" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="0.5596658711855435" STUDY_ID="STD-Martinelli-2012" TOTAL_1="67" TOTAL_2="68" VAR="0.31322588736987333" WEIGHT="10.468127625089046"/>
<DICH_DATA CI_END="0.63925822115772" CI_START="0.08660556871531974" EFFECT_SIZE="0.23529411764705882" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="17" LOG_CI_END="-0.19432367803690415" LOG_CI_START="-1.0624541820637188" LOG_EFFECT_SIZE="-0.6283889300503115" MODIFIED="2009-09-17 07:04:32 +0100" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="0.5099441553806521" STUDY_ID="STD-Mello-2005" TOTAL_1="41" TOTAL_2="41" VAR="0.2600430416068866" WEIGHT="25.612316524071815"/>
<DICH_DATA CI_END="0.969930010824805" CI_START="0.11455580286316215" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.013259602856665482" LOG_CI_START="-0.9409829065826595" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2009-09-17 07:04:41 +0100" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.5449492609130661" STUDY_ID="STD-Rey-2009" TOTAL_1="55" TOTAL_2="55" VAR="0.29696969696969694" WEIGHT="18.079282252285985"/>
<DICH_DATA CI_END="1.2724280325675583" CI_START="0.1148935483064623" EFFECT_SIZE="0.38235294117647056" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.10463322838196014" LOG_CI_START="-0.9397043578527969" LOG_EFFECT_SIZE="-0.41753556473541836" MODIFIED="2009-09-17 07:04:53 +0100" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="0.6134490677087217" STUDY_ID="STD-Yu-2004a" TOTAL_1="68" TOTAL_2="39" VAR="0.3763197586726998" WEIGHT="11.489637319209786"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5545355252584048" CI_END="0.5986159049905991" CI_START="0.2889501985817064" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.41589684372594304" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="77" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="-0.2228517483079106" LOG_CI_START="-0.5391770027275872" LOG_EFFECT_SIZE="-0.3810143755177489" METHOD="MH" MODIFIED="2013-05-01 05:44:13 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.4596603400552218" P_Q="1.0" P_Z="2.3404169633163434E-6" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="259" TOTAL_2="260" WEIGHT="100.0" Z="4.721560755411854">
<NAME>Apgar score less than 7 at 5 minutes age</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8184996479415465" CI_START="0.3054369059641353" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="34" LOG_CI_END="-0.08698150305359936" LOG_CI_START="-0.515078488274363" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2012-08-29 04:15:46 +0100" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.25146628823293005" STUDY_ID="STD-Gris-2010" TOTAL_1="80" TOTAL_2="80" VAR="0.06323529411764706" WEIGHT="44.16859122401848"/>
<DICH_DATA CI_END="0.5736959825826519" CI_START="0.184113194456234" EFFECT_SIZE="0.325" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="40" LOG_CI_END="-0.24131819133822263" LOG_CI_START="-0.7349150867040285" LOG_EFFECT_SIZE="-0.4881166390211256" MODIFIED="2012-08-29 04:22:13 +0100" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="0.28994125968191226" STUDY_ID="STD-Gris-2011" TOTAL_1="112" TOTAL_2="112" VAR="0.08406593406593407" WEIGHT="51.96304849884527"/>
<DICH_DATA CI_END="3.9213915199771665" CI_START="0.11674693738284159" EFFECT_SIZE="0.6766169154228856" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5934402053394905" LOG_CI_START="-0.9327545034400332" LOG_EFFECT_SIZE="-0.16965714905027135" MODIFIED="2012-08-29 04:30:32 +0100" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="0.8964943267227427" STUDY_ID="STD-Martinelli-2012" TOTAL_1="67" TOTAL_2="68" VAR="0.8037020778460637" WEIGHT="3.868360277136259"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.847162588651507" CI_END="1.5314897049865612" CI_START="0.24801151162876492" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6163011250822185" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="53" I2="79.68958081077156" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.18511408172858215" LOG_CI_START="-0.6055281606220807" LOG_EFFECT_SIZE="-0.2102070394467493" METHOD="MH" MODIFIED="2013-05-01 05:44:13 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.007273051209843229" P_Q="1.0" P_Z="0.29732536362302087" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.5137898182232205" TOTALS="YES" TOTAL_1="208" TOTAL_2="208" WEIGHT="100.0" Z="1.042186224170125">
<NAME>NICU admission</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0057044642290205" CI_START="0.19032057309871173" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" LOG_CI_END="0.00247037792561449" LOG_CI_START="-0.7205142632089504" LOG_EFFECT_SIZE="-0.3590219426416679" MODIFIED="2012-08-29 04:18:33 +0100" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="0.42468475703413566" STUDY_ID="STD-Gris-2010" TOTAL_1="80" TOTAL_2="80" VAR="0.18035714285714283" WEIGHT="31.073044390791388"/>
<DICH_DATA CI_END="0.6948735268358536" CI_START="0.19348045256040322" EFFECT_SIZE="0.36666666666666664" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="30" LOG_CI_END="-0.1580942336768776" LOG_CI_START="-0.7133629054459972" LOG_EFFECT_SIZE="-0.4357285695614374" MODIFIED="2012-08-29 04:22:42 +0100" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.3261675664214353" STUDY_ID="STD-Gris-2011" TOTAL_1="112" TOTAL_2="112" VAR="0.10638528138528139" WEIGHT="34.77930563319796"/>
<DICH_DATA CI_END="2.799769271617916" CI_START="0.7289230392014682" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.44712224270224005" LOG_CI_START="-0.1373183227307537" LOG_EFFECT_SIZE="0.1549019599857432" MODIFIED="2012-08-29 04:27:28 +0100" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.34330328116279757" STUDY_ID="STD-Kingdom-2011" TOTAL_1="16" TOTAL_2="16" VAR="0.11785714285714285" WEIGHT="34.14764997601065"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3178682181212276" CI_END="1.4616891596989512" CI_START="0.23407295314405802" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5849289684990735" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.16485502612354208" LOG_CI_START="-0.6306487656237427" LOG_EFFECT_SIZE="-0.23289686975010032" METHOD="MH" MODIFIED="2013-06-18 12:30:34 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.5174025710857821" P_Q="1.0" P_Z="0.25112398758276566" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="259" TOTAL_2="260" WEIGHT="100.0" Z="1.14762363563271">
<NAME>Fetal death</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.001674334280597" CI_START="0.07993308264978286" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.30139342063094" LOG_CI_START="-1.097273437975015" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2012-08-29 04:17:20 +0100" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="0.8215838362577492" STUDY_ID="STD-Gris-2010" TOTAL_1="80" TOTAL_2="80" VAR="0.675" WEIGHT="41.69240271772699"/>
<DICH_DATA CI_END="1.9499102740867493" CI_START="0.1282110276161752" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2900146275853146" LOG_CI_START="-0.892074618913277" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2012-08-29 04:23:05 +0100" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.6943650748294136" STUDY_ID="STD-Gris-2011" TOTAL_1="112" TOTAL_2="112" VAR="0.4821428571428571" WEIGHT="50.030883261272386"/>
<DICH_DATA CI_END="21.858510371159987" CI_START="0.18849839180092154" EFFECT_SIZE="2.029850746268657" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3396205620222488" LOG_CI_START="-0.7246923506834666" LOG_EFFECT_SIZE="0.3074641056693911" MODIFIED="2012-08-29 04:30:56 +0100" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="1.2125876234370572" STUDY_ID="STD-Martinelli-2012" TOTAL_1="67" TOTAL_2="68" VAR="1.4703687445127305" WEIGHT="8.276714021000616"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.31993413123456704" CI_END="1.3586569545672573" CI_START="0.06008334391312567" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.13310981615477302" LOG_CI_START="-1.2212459048553244" LOG_EFFECT_SIZE="-0.5440680443502757" METHOD="MH" MODIFIED="2013-06-18 12:30:41 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.5716473594877746" P_Q="1.0" P_Z="0.1153250956498005" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="192" TOTAL_2="192" WEIGHT="100.0" Z="1.5747026508964423">
<NAME>Neonatal death</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.40443983762499" CI_START="0.0462582631153618" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7327506866268731" LOG_CI_START="-1.3348106779548357" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2012-08-29 04:17:58 +0100" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="1.2144957801491119" STUDY_ID="STD-Gris-2010" TOTAL_1="80" TOTAL_2="80" VAR="1.475" WEIGHT="28.571428571428573"/>
<DICH_DATA CI_END="1.6846540570845736" CI_START="0.0237437471698036" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.22651073219600026" LOG_CI_START="-1.624450740868038" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2012-08-29 04:23:22 +0100" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="1.0872639316848771" STUDY_ID="STD-Gris-2011" TOTAL_1="112" TOTAL_2="112" VAR="1.1821428571428572" WEIGHT="71.42857142857143"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-05-01 05:44:41 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Triazolopyrimidine (Trapidil) versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1630238209396024" CI_START="0.12447807779547992" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3804878048780488" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" I2="0.0" I2_Q="100.00000000000001" ID="CMP-002.01" LOG_CI_END="0.06558860999644207" LOG_CI_START="-0.9049071267269898" LOG_EFFECT_SIZE="-0.4196592583652739" METHOD="MH" MODIFIED="2013-05-01 05:44:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.09006686142054658" Q="3.7927829652422244E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="82" TOTAL_2="78" WEIGHT="100.0" Z="1.6950451218913989">
<NAME>Pre-eclampsia</NAME>
<GROUP_LABEL_1>Triazolopyrimidine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours triazolopyrimidin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1630238209396024" CI_START="0.12447807779547992" EFFECT_SIZE="0.3804878048780488" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.06558860999644207" LOG_CI_START="-0.9049071267269898" LOG_EFFECT_SIZE="-0.4196592583652739" MODIFIED="2009-09-24 01:58:18 +0100" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.5700739997827191" STUDY_ID="STD-Nieder-1995" TOTAL_1="82" TOTAL_2="78" VAR="0.3249843652282676" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-06-18 12:38:25 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Unfractionated heparin versus low molecular weight heparin</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-18 12:38:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Major neurodevelopmental delay at child follow-up</NAME>
<GROUP_LABEL_1>Unfractionated heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>LMWH</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours unfract. heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LMWH</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 07:10:32 +0100" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.0" STUDY_ID="STD-Yu-2004a" TOTAL_1="37" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-05-01 05:45:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Antepartum haemorrhage (after 20 weeks and requiring hospitalisation)</NAME>
<GROUP_LABEL_1>Unfractionated heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>LMWH</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours unfract. heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LMWH</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 07:10:50 +0100" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="0.0" STUDY_ID="STD-Yu-2004a" TOTAL_1="37" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-05-01 05:45:22 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Thrombocytopaenia</NAME>
<GROUP_LABEL_1>Unfractionated heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>LMWH</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours unfract. heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LMWH</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 07:11:05 +0100" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.0" STUDY_ID="STD-Yu-2004a" TOTAL_1="37" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.04917746449907" CI_START="0.22405983586143133" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2567567567567568" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.8481384441588128" LOG_CI_START="-0.6496359865128949" LOG_EFFECT_SIZE="0.09925122882295893" METHOD="MH" MODIFIED="2013-05-01 05:45:22 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.7950510802414656" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="31" WEIGHT="100.0" Z="0.25975718363292244">
<NAME>Preterm birth prior to 37 weeks' gestation</NAME>
<GROUP_LABEL_1>Unfractionated heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>LMWH</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours unfract. heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LMWH</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.049177464499069" CI_START="0.22405983586143138" EFFECT_SIZE="1.2567567567567568" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8481384441588128" LOG_CI_START="-0.6496359865128948" LOG_EFFECT_SIZE="0.09925122882295893" MODIFIED="2009-09-17 07:11:53 +0100" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.8798001146795659" STUDY_ID="STD-Yu-2004a" TOTAL_1="37" TOTAL_2="31" VAR="0.7740482417901773" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.607176815264474" CI_START="0.12519174365998176" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8378378378378378" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.7487442512443707" LOG_CI_START="-0.9024243117098155" LOG_EFFECT_SIZE="-0.07684003023272232" METHOD="MH" MODIFIED="2013-05-01 05:45:22 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.8552525543432633" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="31" WEIGHT="100.0" Z="0.18242073547918364">
<NAME>Infant birthweight less than 10th centile for gestational age</NAME>
<GROUP_LABEL_1>Unfractionated heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>LMWH</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours unfract. heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LMWH</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.607176815264474" CI_START="0.12519174365998176" EFFECT_SIZE="0.8378378378378378" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7487442512443707" LOG_CI_START="-0.9024243117098155" LOG_EFFECT_SIZE="-0.07684003023272232" MODIFIED="2009-09-17 07:11:45 +0100" MODIFIED_BY="[Empty name]" ORDER="24" O_E="0.0" SE="0.9699045872954948" STUDY_ID="STD-Yu-2004a" TOTAL_1="37" TOTAL_2="31" VAR="0.940714908456844" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-07-12 15:46:40 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-07-12 15:46:40 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAdE0lEQVR42u1da3Ab13U+fOwLgEjskqxFqfGYopp2Rv2ROpViyaJi
g1EStUmcZJqZjOO8PFPZidNkOsk0iTvjOv0RW07k1PU4D9kzil9pM/Z4audh2ZLg2JDyoDrqdBql
GYeUFDki6IrcJSWCC2BBsPe1i108SBAEIEA6nx6Lvfece84uzt57d3G/PQAIRMPQATqeBESDYHXi
OUA0DhheCAwvBIYXAoHhhcDwQmB4IRAYXojLhm48BfWFhafA96Qew+sqGg+a5FoOB0cEzr0QGF4I
BIYXAsMLgeHVNjCbrohoUHjFCORQsmzV5Tq2jRVs65EVPKygGCsvvWRgGDW894rH41PScEsd23bi
Vbm+yf59bYrukRbt52zs7ZoxOBpncgADmqyQyzkWVWWyGQsp9BGuE5bDDi1U5IO2KiWYuC0paoLW
SRGHSqp6jHcN5J8ZUsImU1BsUqfSJkUZsFajRMiJ8FZ798i2106sVxU+xNgfWs6lXLvP2H1gy4rG
bMtUB7y2HHW0oBhSQgUfmF2NtQTQr8kqOa6ELKv9IC0MYxw1Y+61SQK4FM6GU+RzfjJCNjE1uUh2
+p7Pyn20MHn0s4OTF0eZdE8kc/hdpG7coXWxlyZ9ncC1c5lDOlOY7QW4WTtrF8oAtsrJPG3Vyiq0
VXj6aI/XDnRNwnw4O5sivQzrZ/qe5+Xg2v37Y8z2y9T2LPeLtUU/RbX/XnAVdSWjXuv5wOyeH+fS
KTMbWgAYjWQPzwMcy2IcNTq86NwrNwuQngbzRrJ/1qCb3LgxQ3Yy18NEmmxnjJHtpw1tJ9NQnMSW
DKkbBJNsnC2G78eEnAQjGmuFCucmBu1CGYB2mrcqMU04Y4yMeO3AuAH2NGg3uk19VNg+49pd3EJs
Z7lt0QL7ZGWopem058MEjOc8HygsY5BL2xo7SCnTv4WIb8lhHFVAvZhCsTjYxkXSe81syuW3x+k+
/Sdn2YbukY+ikP0jARX92OM9F9hwSK5/yfEk6YYXuntxd0rNO4q9Bzwh+VAZlZlNi4vcB6GsZHx2
qU/U9rppn45PG3yKPqfB15I5tJjbEYeZa52Os4PcHxcW/uaY0xtxMjTli+T/22D6oi96TaBzm+Nm
mZt9KXV/6BL5UslNAfnCd3FJ8VjgOC8UOM6UC2VPcFmqecgTOlZQuQ0uFG4OjxHbS367Iya3Pe9v
Umh3+NykTo8EPHbA/KS4tZRfoyNqakq7jTj8OHZTTQjo2cfIbPnoYbuvUJQehn46Dm6GYbVYXE0Y
L5CJmToAehjghMYkj9smjX3Slx3UPMnuzUmNldm8EXsT9JEJlOrAkVChOd4OxdFpO+NFpVps+5en
SKHNbCtJV4e0pZO2fjk8oLKIpD5osPlXAY97Qft39iH/2/F38SP4ETnkU7jspCn95dxuE+Z2Dfra
PJFVO+icKyNnZ4ql1+2W2Uhmy2kSPGf7FSo527v++/Tmv1f+TKETnF0YIl94PCrrl3ifm1GojZmo
tD/sCYl2mB/rmA/d66GcbZnMpNYZ3PafuDqkrRtIW6/YF0mQydewBxB9sh18CDGnDvCWQrczA5Hd
yugcwE4Z46jBc696TeCqfghi27VaMT/2VF89vXY+8LSBc6/yc68u0Frn8CcXq5P70n92Lb76aK1W
9s2kfl5Pr3uTX/PtpTtauS9pCvKa72TgOybqClwM7VsMbeGstFGnFgG4IAeB4YXA8EIgMLwQzQRO
7fHOsYG3NxheV9F4gDRaBF5rCASGFwLDC4HhhUBcIeFlXv6mkVjWvuFlxOhKrVhFeu3GtRFvl9O9
h2/sh1bQuWdVNNqIjWHUOuGVHetftn55Duua8BveN+nbV5ZbBY32nI69XcuEl+lYOe/rMDlT1dEo
DzapyeoRl8NqhmTN9Ni4wOi5doGP26vJCVdPlA1oisJFY7qy17ZVyfYxbal8jHc8J5VtYCiyZjM+
bog7Y4Zl+impKXaBfysLXq7M+bcwEGI+ebZsWdISYMhIo62Epq9WvTeyqP6jBENn6N9HlPl138xC
rzzbm4PfnOxc90TuzFCc1ty/LtVDaobOv/HdFFvD2slkdCkV1jIwlDy3J5YXeroF6z7/c8hHLs13
LrKGz//hs93Rc3/1w0X48mGIkDouT5smeO6nByEfSvXsHod/e+W7F/d3MHsLEP/TDvhmJNSxKFwg
tkLM1hvUFsHQG+cO3MOkha1waOHSMzk48rhTOD5crepfrdr03uuADLJHC3TGYZx8NdnTUhrgRQ2s
HW6NOsFqBBuX4FYmk5mA0wXmLNejXNiHGX/XpbvOGNPbTxsjZO9hCayHPXmOW7cAdJv2+IvE/jbQ
OItI4xzdO05fyLhyQVvAPl3g0sLWN3K2TWm0DnZTFQO6ucsrzY8sARxPGiVMVVJ13acO7Igvx2GF
ouIAvdbpz+3KxH1U3Ep0XEqjNf94can3QhGNNuGsTKPlBcLW2E05iO9k3FoPSOVoEI22Kmi/iMfj
XafEHmWqdriExI2dT13y5EQN+AuAc2JLyjgDthemXygxdyxAxy08dzAWkpGLfhot/eS4DEehW8L9
7Xd9Era2LUyFR/E5RgtN7SlLFdSTYu+BU7BZApA2OaQ4L43T9RuJMVpDOaySX5HLqJthk1pcxtm0
uQB/1x1jHY9bSwOGjWIyGQT3GOwuQBoDQwx3nLcrDzuKK/f5gC32RAPeyt9AIWxphjFJOmMNl520
Snjlxsl/418WF/zH36OkzwH8LhM5DBCe/wr9zhU2gTrXx2oK4DJnMnudmaKymaj0fhJCc08MPldi
bia6N10gckvs1QD/cQ3ACVtKzRIrNyu3CmZur0J5u5Z916wrd19GcoLc33HN5su5hK2XbTlKRK95
HuOoReZeLQBzMLGtnu05kSTSaCvMva5GnqORSdWzuYe+5p98YXhd7eHVUOBiaKTRNuPUIgAX5CAw
vBAYXggEhheimcCpPd45NvD2BsOrXS/YxZY9A0s4OCJw7oXA8EIgMLwQGF4IDK9qYdZJBnFlhBdN
aqYOlKG4xpZlp9ryl8qW+/mwldQ3Lu/dGvi0QlVfKlOXkHvW0GQJjRZ/xa6u94rHpzS+eLOERboM
rbRn7ptly/182Erq2xt8eGa6XDK80aMX19Bm8bFYaeyDqxwcDSvv9Vc6Y7CaGssnG/PyuTphlgoW
3DyvsZG/ZhoGY6QmNInmaSWyLhmVZZKl6gnGaO1XFZ6tVhGEVcFoBb8utyMItBCzmeZYWA6NMb9c
HTOQL9bV48xZjmFJop5pY/7ctbGd/+TLUcvURY7cREhWozy/bYIxdw8G2nNUkY1WyCUkResHSUIa
bbVzL6PAquX5ZH+oJd3nw0ssn2uflLyP7/M8ryJ3K8wk1R8CvNt0aJ5W6JoU5d/Wzi5w8Z1Tz/cB
zB/OzP4NsByvUaY7H8qafHhxdbmdbnnKXek+MEUzxW6dzc7QPGQwCSmuc62SUZ902/L0rOyLHqcj
S7NJ5ZLq1kJ519PUqpujtmuSqh8ROXLf/VKWh/rTR0m79o96PxNo77FJjX8Sck9GMi9/GEC+F+Oo
mvAik6+3PeDtnWEM1md5PlkKnpY1c9p4O99PizyvHDlj/FkvTyvNCcvxwsSgkDlh9GSI0gho47wx
zo+VHMZFhYIut6NOGCfc4cigdlQJNEoonDCgm+u8YwLGXyi0JfQk2OXxDm94nQa+MaEWyrlnru90
r5Aj1x4B60Z26CPEx+z1F9KB9t5uiFy1Qu4Hjr3lAMDr/4BxVAH+xdCUJjpwMeNjkQbyyYoCyhkt
zs4KHsfUHJrVdsR9vFU/MZUKOANf+8p2v8DYTYswzzhnQd1SO+AxXcfemac6paTa4ryyIsct3ZYy
an05asW/sd1uGttySXALOkLOiWY7101zYq43E8PfHJcq02gvFN9pdZaQSb2CYI5Zh3FMN3b0vRaQ
Pu6JjDGB3vz1wXn1toVk6C5+GxnULbRuehlqxSRom50MRcpwbSkCzNlOk6t3FTNqjxfnqGXY1SH7
nDtmFrU34Hok5KTUmzSnrdmB3VSVcy+9q/ixwzBcFyhQNoF+jA+Ov4ZhxSvvh81k5Mj/L8vTWvh2
uoeTe/j+u+Akkb5tZktf4BvUbKPj+3yyV9Cldk56hnVmJ+14M0OqQzYPFHNtKVQHXvOojd2UDz4E
w3JROfNdLb3uOJNXQD45oAb0UnBK8cvRnLafADj1AMZRdXMvOf1qkcCJrBJkp8447itIcnv8eV47
5AyZK4Vv95LR3smSwb5iXycyBn9D/iCR3r7On62WyIQ/LKXm2E749vW+qplbFPc1bwazY/UqC6Jv
oTqzpK0+OV3yyGMmKt3nEbMfpJzcDiV7tqi8yHcX4b9c78u6ru2/aAX0fqa+d8Yvt06XRz9O7llw
al/N3Ktq6NlSouCKmWRjNb8UrnZNMDdelGLxxp5Cp+e8gXOv8nOv1YdXxFnqDl8oKZazK+hJNb+m
aMWml7sSnHn/+2sacjb7AjRaDK8lpNE2DLgYGmm0zTi1CMAFOQgMLwSGFwKB4YVoJnBqj3eODby9
wfBq4njQukNFXR+iIY0WgXMvBIYXAoHhhcDwQmB4NQDmZbZjXiZ/MLwqg5JuQ8lVk24N5aGSsg1N
Olhhxwi7flawv2FV2WgfMjCMGtB7xeNT8u38U0lVZa358BdKynY06WC5HXPhjRXs71hVNtrtC9jb
NWRwNGaPev3VEZaz1QnvdUm3UcafNTXlCL/cOec1tvNtdIfICUaqyP3K2bZmmPNidUV5LcHotuZD
cph/e/2aQts2ZMagTeyV1X5S/UXWji2/93MJcNm1sSOKYtvMH1Efi+7Za3vZaGXD9ZPbo+XCjqPt
NdxstDPCx6i6V2TLTmohno3W9YXZ2yafxDhqyNxLL3AjDk3OMe7r/e4D4PxkOEUk/iX5YSGrZFTd
Jd12P39A7i50B3GIaj0LREbOPEK/9sXk7H3vSzL97dlp/hvD/MuZ7UQkFc6apMXR7dnD86T6/gPT
fQC94UNv3w2MXUutHUoeMQaZP6Ie8k9v73Vt3/Km56c+m3nkOlYu7ESVRxZcOUPiPi5NfryXO7r/
fOhaz5eUZ+/ND2Ic1T+8yOTrLwrP/+9mPNQ7JoyzooDnkdU+4rJwtQkY97g5d1wPE4q/sdwEpawS
mVs0pqtlOItX3QYapwelR+DTN9I8sob9IoD8d/1biMIdEmgfBZDuTdyS9uqILy4vVtSTBj+90zXl
2J6fmgSf5iuthR2H5bcVPp7mPp5heW0p7jOmHc+XnZ49G7PRVkLti6EpQyKxO12WY1vCwoUCm7WY
gVvEtnVlgqRYGhUDOUpdFXlkBYOVVh/PgKNnO8ieuTEPPReK1Y9ngrxY6qPrJ7jM3AD5tuCSj2kb
yEY7kMvtiLv2gjRa/M1xqV7ZaEfypff4wXluZ4B061mjO5/0PwTgbNuADC/3SKw9Sy+eBpZHNvwh
xmDV5nk1iRRpfuonZM+wk6EPlagXMzk+aUIpM1fY2RzMdSt8dJF0vetZunAGPHs4s6+ILtBq1Bwi
Jzi65NAt/0v/hf81/Z0N/gLn0fR3JlgQandLj17qYOVkLHzMPnCsA87PX/p68gxMprvUb0fyOb+M
+Jc78agB7CVKnXPfeoDI7vmfB0MnFkF95c8sOQ/h+S690wH10oN/+/iiW+dTF/Vij9ghDf3227br
Zy7XdfDlHC0Xdm68/VKY7VPT3Ee3NfL/l533HWAFnXMpny+Pgq/3SncsN1S0Kpbq2poXUuk1zb1k
Z6KobCanBJf4WBnlOW7jnKGkT3hTrYycJUFztGfwMWDZX2cXLoW4THDBlHWTLLizR9cx2bsNxqCN
7JZ7LlKOq5yeoHxWZfQorwsH/eH1AjzL7PM5z88TPActKRd2vsry23I54qMTfDtYSHuPVewLsZeT
sJuq+9yrahy8a6GlDtnccKmu8TC2a7LKbLRX39yr0eHV89HHu+Za7Oq2D3yhns1FLvjnFxheSKNt
IHAxNNJom3FqEYALchAYXggMLwQCwwvRTODUHu8cG3h7g+GF40G9nc7h4IjAaw2B4YVAYHghMLwQ
GF5NhllT1WpVTH8VLj+tF5q8YqLqFAYFQTVdUUjkgVxNa0EV3UsHRMpDC64s2SnnqCgrrip6rz0+
mMjpbXQyluHY1pDLNqDiy1VLym/gn+LBPLqlKK7K2djbtc7gKHLHjjHerCPyyX5PHjUSPKesPUpz
zgLj3YY5x1XkoYWCPLj024E9ss0y13LGqyIfTHA+r5dDltQdBJZaVuEMWZoPl19fNFetV87aiyqi
XWJhLJDrlmJME9zffk0e1WlObsrllRYwG20Lzb3yydlegJu1szbn1lJm6t6pH2fex8rhmmeUrUzu
2rnMIc673fqGyEPryYtuJA72L1JRmhc3y3LL5pNHP/v+yaM0Z66VVXjmtT556lNAXz6QnU3x9LeH
M7M8JxLNVeuVM/Lss0nRLo1fYYv7S7H1/DRvM2Vm/4t4PxphXN6BLMZR64QXTxqbmxi06f8wTjuZ
E4b2jjOsXOSOBcaQGOHLjFUDNP4VuvIenNNSppBblueVpazXjAQmZ6BlJgz6O6A9DSL9Lc2Hy3mx
udf95RTX+1bNu7a4v2wqYWi8TZo3lwzaUiZBubyv5zCOKqB2IlpNoAy1O9nmnXfS/V13wr6uRRi6
G9zyoXOwrzNPP+0aGhr6PaOVvZN8Opv3y3NymNcM+X9f9yLV9ZonKufYCvLur8M+UjDzve7utzAV
p2/fq29hzLLO+8BXXvCN/3Vt3ekR0cinbmbc/K7USZSmvnVw/x/2M389pNsyd2hdnc7XhYi2NhR4
syPBCofljgU/g7ajwHb15PlczM0YW5Jb1pdD1mSyb4HpCN/vyfeItJA0V22hvIyHRb457iOLjSDT
vLl9qSntNihm/iJa4LlX9+YkCXJJg82/Clb0sdyxwN4GcJCIHHPgyJibh1bIHzPMd/Gokjc5Chk9
NxfnllWJFn+/inISqGxu2s7wmFmcuUXkw6W5agvlCe8GkMfsAyW+9YLGX4yR/+04nR9qCeNH5Dbi
FC47abnwml0YIl9ivE+2i270O1nuWDrD7pU/86rguCo273CEfCQ1SHs4eT1Y6cgRMsJlinPLzkSl
/ZxRO/NBhcrO8Sy40nrKgRVHLe/0lyvrXWWZfSrNdTunDnDXwrcP0nvP8G5ldA5gp4xxVHHQbTFq
S6Nzxwaee20437f2VmY2VkujvUp6mVwL8xwbnTs2ACM7v/ZGIpJ/hSqGlz+8Wm7a0Mzoqs+Pi0UR
mm/H8GqU0zgrrTOQRtsSU3sEhhcCgeGFwPBCXIXAqX2dgTRapNHieNBIp5FGi8BrDYHhhUBgeCEw
vBAYXpcNZhM01qaHaOXwckLK3p4CUaM46+uGZbPclsM9FTT0SE16FbLRRmwMo3YIrx4leT98tWL1
8jliy+E35TXMG6ya9ASKq87p2Nu1Q3jlJwzj4sM0R6wc4t8YZdKOMQqsLcitmgOO5pbTrqRXdeVj
NmPO0qy3Y4z9KuiwsagqG5QDq0R5xzN8XKpJDwZCGufwDmgsVa4hS1oCDGUTxlEbhFf30BGHLifU
Z7Mv8d8Vrv1ZZnorgK2k3Dy20h/BU5JbTtE16ckPTEl9REfNKCwckoIOC/nJSApgq5oUi+ayP6lN
DzJ/iHC/LoUzs/MA8yHH3A3wY0wX2g7h9cY/fyCsJVmOWMGfdbaBppJ4KOSI/cm98DnFLacYNzz5
c8ZpEpzOOEzQ7/u0twCe58VVJ4wzfD+3pTY9OGNc4FbT04yJ+42cbRPHtmB4VUKLrbU3h3a8uGyO
WHNDWk37ctSyXLGevEgW624q5MWVnNr0fNlo+3O7MnEYuykH8Z1BfgCutW/VN+QoJhhzR8vkiD1e
mDsbXdF9foatK+Ww5wnmpzj7tRzpuJAXt9OsTQ8GXIlemH6BbLYtTIVH8TlGmwyO6SHH7JXIlvNn
aT/D+bPSJkd1g0y+vscrd/WE/HWwidadgs0iw98x/6hlD8N1CT7HO1WbHizAWzmNNnfYpgw2zTAm
l8gGl520Q3hZ90fW586RLc8RS2dFNyu3RgB+x3LEPjBIi/7v2C1euasn5Lv25u4mde9R0ud4heR/
vlXIiyv/ujY9GNfss+zD3BODz9Fpmi1Hieg1z2Mctcfcay1YmYAr8uKaH3tBqkWvAqrPRnv1zb2a
/IacRuL88ilVe5a6f/rqo/TTvplMRy16FfDnzzzoH+HxDTm+N+RgNtp6j/B4CjAbbRNOLQJwQQ4C
wwuB4YVAYHghmgmc2uOdYwNvbzC8cDxYFktrUsHBEYHXGgLDC4HA8EJgeCEwvK5g4ApUDK8GwNgj
s4S1lTi7Fai0CAyvKpBcuDtr6v3L5sCliOOpwvBaPdZrI6Bpac6j1RWpkNc21ruHSTiqyEibCMlK
FMCWFC2BJw7DqxqoE+S/iSzn7OaTF3le2xcpb6PraSbx2OQhnofo3S9lQ2QY/UIk8/KTeOIqAFer
BqdWbNRTMozn+KxBN5TESAueZQvqY/dvc9mQXDwCF2zfUvs2XWtfGbX8KKRfqSdjrWCZHN27Rh41
N8ZisSVvD7a5C9PN3ghdU24t9Qz244nDwbEaZIbJf8NSIOIClF1KpeUfNnTIlMUmpd4MzeOJw/Cq
BlN2AhL27wCOe0zajAOvhQoSKTjFqbRL0jhdbqLaxgufwBNXAVcQEa0e2H9p+tzT1kMkaroXRT74
XLTj/PSCyNYOQ089+QOri+7Nj971nVNnQO/sfGL/wUIL7UlEqy+QiNYw4NQep/aIJgFXq9YbeTwF
GF4NA8418M4RgeGFwPBCIDC8EBheCAwvBALDC4HhhcDwQqwK1mXWb60GMLwQ2HshMLwQiCLgeq8W
m3tdCcAXjzfh3NYYnmu93FugARwcETj3QmB4IRA4tUdcjvscnNo34t5RZxu9+mmyp8O2q1ItTKf1
2mwXpuN61R7wqoLXlYxieNU9uvhJZn+rji73i9HFXvWqgRvWWmwX1C2o1gOr6EgrGsW5Vws9zKj9
kYCl1+26qKs17L0a3JHVMq7WoGoVP3BbvW29ag/0qg8Yw6tRHZJF/1pV3zm5YyPZrlYVPM0abZe0
U5MH5XQwvBo54ImZySrHyBpU9TXbXqsH5XVw7tUaY6O1xqFt7eOyvvbZXKkOhlcLRWLtP4fX64f0
ev8gj49V6x8q/qcE1Z1e31On1aoGja6hAX01zpd77lVGx8LwQjTwSsPBEdFAYHghMLwQGF4IBIYX
AsMLcUXA96MQclwQdYJeJrzwCRiiPrBwcETg3AuB4YVAYHghMLwQVxa6l5/5t989Jfre8uFV3Kfl
2/iIcu3ke1GyvqV2jy4cHBEYXogrPrysKmtL5CyrUHqZfniyyhq32uJ4PN8rudTKp75eRLSVXkfQ
bnPVFjwevQ1P/eoHR8sSV5J3ZVjsj6jxX3Fc0iq6koRYQbqp3Zhr3H807sZq6ePhtiDgf6uf+lX3
XuXeRGDpwRr/vvtWC49gGXzxRdPjSy/8LXWm4GtrHg+1EzDe6qe+xsFRt8Sfon5XL+mTS/pm/bL2
13pZ23pw21rHYxWd+VIHW/fU1/ElALrvJVUrny7daomZ2DLz3lY5nioYti176rvrex7o1bPCqwks
30vKLn986QGf2vZ4WtXVWp976ew9KnotTy58NwVNO/tWycBhrfDUolWPx1rLQ6Omn/ruVR6YXrln
LdTwuAtK6pZXyWuaOjgWWfM7Qz8Jn1r+eMr62cqn3vcSgMLVXczdzrfTz8LFvzm2k+/FvznqKz3M
atHj0Ct8GYjW/t6gzVZRYHi1E9pugU758Mq38VeQa2Pfl66066H7irhI0PcWBS7IQWB4ITC8EAgM
LwSGFwLDC4FYHv4HE/gGJkTjwgvfv4TAwRGB4YVAYHghMLwQGF4IBIYXAsMLgUAgVsb/A2vtFEac
tG8TAAAAAElFTkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-07-12 15:46:40 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVcAAAKBCAIAAABs3H/gAAAf1ElEQVR42u3dv44cxfrG8ZGQEMEG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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-09-22 05:13:26 +0100" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2013-07-12 15:54:56 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-07-12 15:54:56 +0100" MODIFIED_BY="Denise Atherton" NO="1">
<TITLE MODIFIED="2012-08-28 11:39:47 +0100" MODIFIED_BY="Denise Atherton">Methods used to assess trials included in previous versions of this review</TITLE>
<APPENDIX_BODY MODIFIED="2013-07-12 15:54:56 +0100" MODIFIED_BY="Denise Atherton">
<P>The following methods were used to assess <LINK REF="STD-Kincaid_x002d_Smith-1995" TYPE="STUDY">Kincaid-Smith 1995</LINK>; <LINK REF="STD-Mello-2005" TYPE="STUDY">Mello 2005</LINK>; <LINK REF="STD-Nieder-1995" TYPE="STUDY">Nieder 1995</LINK>; <LINK REF="STD-Rey-2009" TYPE="STUDY">Rey 2009</LINK>; <LINK REF="STD-Yu-2004a" TYPE="STUDY">Yu 2004a</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Selection of studies  </HEADING>
<P>Two<I> </I>review authors independently assessed for inclusion all the potential studies we identified as a result of the search strategy. We resolved any disagreement through discussion or, if required, we consulted a third person.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction and management  </HEADING>
<P>We designed a form to extract data. For eligible studies, at least two review authors (JD and RW) extracted the data using the agreed form. We resolved discrepancies through discussion or, if required, we consulted a third person. We entered data into Review Manager software (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>) and checked for accuracy.</P>
<P>When information regarding any of the above was unclear, we attempted to contact authors of the original reports to provide further details.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of risk of bias in included studies  </HEADING>
<P>Two review authors independently assessed risk of bias for each study using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). We resolved any disagreement by discussion or by involving a third assessor.</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Sequence generation (checking for possible selection bias)</HEADING>
<P>We described for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.</P>
<P>We assessed the method as:</P>
<UL>
<LI>adequate (any truly random process, e.g. random number table; computer random number generator);</LI>
<LI>inadequate (any non random process, e.g. odd or even date of birth; hospital or clinic record number); or</LI>
<LI>unclear.   </LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4"> (2) Allocation concealment (checking for possible selection bias)</HEADING>
<P>We described for each included study the method used to conceal the allocation sequence in sufficient detail and determine whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>adequate (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);</LI>
<LI>inadequate (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);</LI>
<LI>unclear.   </LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3) Blinding (checking for possible performance bias)</HEADING>
<P>We described for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We judged studies at low risk of bias if they were blinded, or if we judged that the lack of blinding could not have affected the results. We assessed blinding separately for different outcomes or classes of outcomes.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>adequate, inadequate or unclear for participants;</LI>
<LI>adequate, inadequate or unclear for personnel;</LI>
<LI>adequate, inadequate or unclear for outcome assessors.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(4) Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations)</HEADING>
<P>We described for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes.  Where sufficient information was reported, or was supplied by the trial authors, we will re-include missing data in the analyses which were undertaken. We considered more than 20% incomplete data to be inadequate. We assessed methods as:</P>
<UL>
<LI>adequate;</LI>
<LI>inadequate:</LI>
<LI>unclear.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(5) Selective reporting bias</HEADING>
<P>We described for each included study how we investigated the possibility of selective outcome reporting bias and what we found.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>adequate (where it is clear that all of the study&#8217;s pre-specified outcomes and all expected outcomes of interest to the review have been reported);</LI>
<LI>inadequate (where not all the study&#8217;s pre-specified outcomes have been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);</LI>
<LI>unclear.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(6) Other sources of bias</HEADING>
<P>We described for each included study any important concerns we have about other possible sources of bias.</P>
<P>We assessed whether each study was free of other problems that could put it at risk of bias:</P>
<UL>
<LI>yes;</LI>
<LI>no;</LI>
<LI>unclear.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(7) Overall risk of bias</HEADING>
<P>We made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the <I>Handbook</I> (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered it likely to impact on the findings.  We explored the impact of the level of bias through undertaking <LINK TAG="SENSITIVITY_ANALYSIS" TYPE="SECTION">Sensitivity analysis</LINK>. </P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Measures of treatment effect  </HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>For dichotomous data, we present results as summary risk ratio with 95% confidence intervals.<I> </I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>For continuous data, we have used the mean difference if outcomes were measured in the same way between trials. We used the standardised mean difference to combine trials that measure the same outcome, but used different methods. <B> </B>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Unit of analysis issues  </HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Cluster-randomised trials</HEADING>
<P>We did not identify any eligible cluster-randomised trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cross-over trials</HEADING>
<P>We did not consider cross-over trials an appropriate study design for the evaluation of this intervention and we have not included them.<B> </B>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dealing with missing data  </HEADING>
<P>For included studies, we have noted levels of attrition. We have explored the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis.</P>
<P>For all outcomes we have carried out analyses, as far as possible, on an intention-to-treat basis; i.e. we attempted to include all participants randomised to each group in the analyses. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes were known to be missing.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of heterogeneity  </HEADING>
<P>We used the I² statistic to measure heterogeneity among the trials in each analysis. If we had identified substantial heterogeneity (greater than 50%) in a fixed-effect meta-analysis, we would have noted this and repeated the analysis using a random-effects method.<B> </B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of reporting biases  </HEADING>
<P>Where we suspected reporting bias (<I>see</I> &#8216;Selective reporting bias&#8217; above), we attempted to contact study authors asking them to provide missing outcome data. Where this was not possible, and the missing data were thought to introduce serious bias, we have explored the impact of including such studies in the overall assessment of results by a sensitivity analysis<B>. </B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data synthesis  </HEADING>
<P>We carried out statistical analysis using the Review Manager software (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>). We used fixed-effect inverse variance meta-analysis for combining data where trials were examining the same intervention, and the trials&#8217; populations and methods were judged sufficiently similar. If we had identified clinical or methodological heterogeneity between studies sufficient to suggest that treatment effects may differ between trials we would have used random-effects meta-analysis.</P>
<P>If we had identified substantial heterogeneity in a fixed-effect meta-analysis we would have noted this and repeated the analysis using a random-effects method.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis and investigation of heterogeneity  </HEADING>
<P>We had planned to carry out the following subgroup analyses had we identified substantial heterogeneity:</P>
<OL>
<LI>antithrombotic agent administered (unfractionated heparin versus low molecular weight heparin versus other);</LI>
<LI>gestational age treatment commenced (first trimester versus second trimester versus third trimester).</LI>
</OL>
<P>We would have used the primary outcomes in subgroup analysis.</P>
<P>For fixed-effect meta-analyses we conducted planned subgroup analyses classifying whole trials by interaction tests as described by <LINK REF="REF-Deeks-2001" TYPE="REFERENCE">Deeks 2001</LINK>. For random-effects meta-analyses we assessed differences between subgroups by inspection of the subgroups&#8217; confidence intervals; non-overlapping confidence intervals indicate a statistically significant difference in treatment effect between the subgroups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis  </HEADING>
<P>We did not carry out sensitivity analysis.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2009-09-22 05:13:26 +0100" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>